TR201820740A2 - Özgün bi̇snaftali̇mi̇dopropi̇l (bnip) türevi̇ akti̇f i̇laç etken maddeleri̇ - Google Patents
Özgün bi̇snaftali̇mi̇dopropi̇l (bnip) türevi̇ akti̇f i̇laç etken maddeleri̇ Download PDFInfo
- Publication number
- TR201820740A2 TR201820740A2 TR2018/20740A TR201820740A TR201820740A2 TR 201820740 A2 TR201820740 A2 TR 201820740A2 TR 2018/20740 A TR2018/20740 A TR 2018/20740A TR 201820740 A TR201820740 A TR 201820740A TR 201820740 A2 TR201820740 A2 TR 201820740A2
- Authority
- TR
- Turkey
- Prior art keywords
- formula
- bnip
- bisnaphthalimidopropyl
- structure indicated
- derivative molecule
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 239000004615 ingredient Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 201000010099 disease Diseases 0.000 claims abstract description 31
- 230000003612 virological effect Effects 0.000 claims abstract description 14
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 230000001580 bacterial effect Effects 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- -1 alkyl cyanide Chemical compound 0.000 claims description 68
- 150000001875 compounds Chemical class 0.000 claims description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 9
- 150000001298 alcohols Chemical class 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 229940124530 sulfonamide Drugs 0.000 claims description 9
- 150000003456 sulfonamides Chemical class 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 8
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 208000035143 Bacterial infection Diseases 0.000 claims description 7
- 241000222697 Leishmania infantum Species 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 6
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 208000030852 Parasitic disease Diseases 0.000 claims description 6
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 6
- 229960002418 ivermectin Drugs 0.000 claims description 6
- 201000004792 malaria Diseases 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- 235000015320 potassium carbonate Nutrition 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- 229960005053 tinidazole Drugs 0.000 claims description 6
- 108010074328 Interferon-gamma Proteins 0.000 claims description 5
- 102000008070 Interferon-gamma Human genes 0.000 claims description 5
- 208000004554 Leishmaniasis Diseases 0.000 claims description 5
- 201000009906 Meningitis Diseases 0.000 claims description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 5
- 230000002141 anti-parasite Effects 0.000 claims description 5
- 230000000840 anti-viral effect Effects 0.000 claims description 5
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims description 5
- 229940028894 interferon type ii Drugs 0.000 claims description 5
- 229960000282 metronidazole Drugs 0.000 claims description 5
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 claims description 5
- 229960005322 streptomycin Drugs 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 claims description 5
- 229960004546 thiabendazole Drugs 0.000 claims description 5
- 239000004308 thiabendazole Substances 0.000 claims description 5
- 235000010296 thiabendazole Nutrition 0.000 claims description 5
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 claims description 4
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 108010092160 Dactinomycin Proteins 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 4
- 208000016604 Lyme disease Diseases 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 claims description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 4
- 206010035148 Plague Diseases 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 206010047505 Visceral leishmaniasis Diseases 0.000 claims description 4
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 claims description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 4
- 201000008680 babesiosis Diseases 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 229960002682 cefoxitin Drugs 0.000 claims description 4
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 claims description 4
- 229960002580 cefprozil Drugs 0.000 claims description 4
- 229960001668 cefuroxime Drugs 0.000 claims description 4
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- 201000003146 cystitis Diseases 0.000 claims description 4
- 229960000640 dactinomycin Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229960001625 furazolidone Drugs 0.000 claims description 4
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 claims description 4
- 229960003439 mebendazole Drugs 0.000 claims description 4
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 claims description 4
- 229960003775 miltefosine Drugs 0.000 claims description 4
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 4
- 229960002480 nitazoxanide Drugs 0.000 claims description 4
- 230000003071 parasitic effect Effects 0.000 claims description 4
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 claims description 4
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims description 4
- 229960004448 pentamidine Drugs 0.000 claims description 4
- 229960000996 pyrantel pamoate Drugs 0.000 claims description 4
- 229960005224 roxithromycin Drugs 0.000 claims description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 208000019206 urinary tract infection Diseases 0.000 claims description 4
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 3
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 3
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 claims description 3
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 claims description 3
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 claims description 3
- WZPBZJONDBGPKJ-VEHQQRBSSA-L 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfonatoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoate Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C([O-])=O)\C1=CSC(N)=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-L 0.000 claims description 3
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims description 3
- 108010001478 Bacitracin Proteins 0.000 claims description 3
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 239000004100 Oxytetracycline Substances 0.000 claims description 3
- 241001631646 Papillomaviridae Species 0.000 claims description 3
- 201000007100 Pharyngitis Diseases 0.000 claims description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 239000004187 Spiramycin Substances 0.000 claims description 3
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims description 3
- 239000004098 Tetracycline Substances 0.000 claims description 3
- 229960002669 albendazole Drugs 0.000 claims description 3
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 claims description 3
- 239000003096 antiparasitic agent Substances 0.000 claims description 3
- 229960003644 aztreonam Drugs 0.000 claims description 3
- 229960003071 bacitracin Drugs 0.000 claims description 3
- 229930184125 bacitracin Natural products 0.000 claims description 3
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 3
- 201000000053 blastoma Diseases 0.000 claims description 3
- 229960003719 cefdinir Drugs 0.000 claims description 3
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims description 3
- 229960004069 cefditoren Drugs 0.000 claims description 3
- KMIPKYQIOVAHOP-YLGJWRNMSA-N cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 claims description 3
- 229960002129 cefixime Drugs 0.000 claims description 3
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims description 3
- 229960004682 cefoperazone Drugs 0.000 claims description 3
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 3
- 229960004261 cefotaxime Drugs 0.000 claims description 3
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims description 3
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 claims description 3
- 229960005090 cefpodoxime Drugs 0.000 claims description 3
- 229960002398 demeclocycline Drugs 0.000 claims description 3
- 229960003974 diethylcarbamazine Drugs 0.000 claims description 3
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 claims description 3
- 229960003722 doxycycline Drugs 0.000 claims description 3
- 201000008184 embryoma Diseases 0.000 claims description 3
- 206010014665 endocarditis Diseases 0.000 claims description 3
- 206010020113 hirudiniasis Diseases 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 201000005047 leech infestation Diseases 0.000 claims description 3
- 229960003907 linezolid Drugs 0.000 claims description 3
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 3
- 229960004023 minocycline Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229960003702 moxifloxacin Drugs 0.000 claims description 3
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 3
- 229960000564 nitrofurantoin Drugs 0.000 claims description 3
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 3
- 229960000625 oxytetracycline Drugs 0.000 claims description 3
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 3
- 235000019366 oxytetracycline Nutrition 0.000 claims description 3
- 229960001294 spiramycin Drugs 0.000 claims description 3
- 235000019372 spiramycin Nutrition 0.000 claims description 3
- 229930191512 spiramycin Natural products 0.000 claims description 3
- 229960000654 sulfafurazole Drugs 0.000 claims description 3
- 208000004441 taeniasis Diseases 0.000 claims description 3
- 229960003865 tazobactam Drugs 0.000 claims description 3
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims description 3
- 229960003250 telithromycin Drugs 0.000 claims description 3
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 claims description 3
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 3
- 229960002180 tetracycline Drugs 0.000 claims description 3
- 229930101283 tetracycline Natural products 0.000 claims description 3
- 235000019364 tetracycline Nutrition 0.000 claims description 3
- 150000003522 tetracyclines Chemical class 0.000 claims description 3
- 229960005041 troleandomycin Drugs 0.000 claims description 3
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 claims description 3
- CIDUJQMULVCIBT-MQDUPKMGSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4-amino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](NC)[C@@](C)(O)CO1)O)NCC)[C@H]1OC(CN)=CC[C@H]1N CIDUJQMULVCIBT-MQDUPKMGSA-N 0.000 claims description 2
- STIGEALBGPUGBV-UHFFFAOYSA-M (4-aminophenyl)-(carbamoylamino)oxystibinic acid Chemical compound NC(=O)NO[Sb](O)(=O)C1=CC=C(N)C=C1 STIGEALBGPUGBV-UHFFFAOYSA-M 0.000 claims description 2
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 claims description 2
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 claims description 2
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 claims description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 claims description 2
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 claims description 2
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 claims description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
- 239000005660 Abamectin Substances 0.000 claims description 2
- 206010063409 Acarodermatitis Diseases 0.000 claims description 2
- 241000701242 Adenoviridae Species 0.000 claims description 2
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 2
- 240000005528 Arctium lappa Species 0.000 claims description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 2
- 206010053555 Arthritis bacterial Diseases 0.000 claims description 2
- 241001533362 Astroviridae Species 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010061695 Biliary tract infection Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 241000588807 Bordetella Species 0.000 claims description 2
- 241000589968 Borrelia Species 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 241000589562 Brucella Species 0.000 claims description 2
- 108010037003 Buserelin Proteins 0.000 claims description 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 2
- 241000714198 Caliciviridae Species 0.000 claims description 2
- 241000589876 Campylobacter Species 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- 208000005024 Castleman disease Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000024699 Chagas disease Diseases 0.000 claims description 2
- 206010008631 Cholera Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 2
- 206010009344 Clonorchiasis Diseases 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims description 2
- 108010078777 Colistin Proteins 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000003606 Congenital Rubella Syndrome Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 206010010619 Congenital rubella infection Diseases 0.000 claims description 2
- 206010061788 Corneal infection Diseases 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 241000186216 Corynebacterium Species 0.000 claims description 2
- 206010011416 Croup infectious Diseases 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 201000000077 Cysticercosis Diseases 0.000 claims description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 2
- 108010013198 Daptomycin Proteins 0.000 claims description 2
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 claims description 2
- 206010014096 Echinococciasis Diseases 0.000 claims description 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000004145 Endometritis Diseases 0.000 claims description 2
- 108010032976 Enfuvirtide Proteins 0.000 claims description 2
- 241000194033 Enterococcus Species 0.000 claims description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 2
- 201000006353 Filariasis Diseases 0.000 claims description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 2
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 206010017916 Gastroenteritis staphylococcal Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 2
- 108010069236 Goserelin Proteins 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 241000589989 Helicobacter Species 0.000 claims description 2
- 241000700586 Herpesviridae Species 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 2
- 206010021531 Impetigo Diseases 0.000 claims description 2
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 2
- 229930010555 Inosine Natural products 0.000 claims description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 2
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 2
- 241000589248 Legionella Species 0.000 claims description 2
- 241000122138 Leishmania arabica Species 0.000 claims description 2
- 241000222740 Leishmania braziliensis Species 0.000 claims description 2
- 241000178949 Leishmania chagasi Species 0.000 claims description 2
- 241000346663 Leishmania colombiensis Species 0.000 claims description 2
- 241000892935 Leishmania deanei Species 0.000 claims description 2
- 241001232212 Leishmania donovani archibaldi Species 0.000 claims description 2
- 241000203282 Leishmania herreri Species 0.000 claims description 2
- 241000222693 Leishmania lainsoni Species 0.000 claims description 2
- 241000222734 Leishmania mexicana Species 0.000 claims description 2
- 241000012072 Leishmania mexicana venezuelensis Species 0.000 claims description 2
- 241000222695 Leishmania panamensis Species 0.000 claims description 2
- 241000222705 Leishmania pifanoi Species 0.000 claims description 2
- 206010024229 Leprosy Diseases 0.000 claims description 2
- 206010024238 Leptospirosis Diseases 0.000 claims description 2
- 108010000817 Leuprolide Proteins 0.000 claims description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims description 2
- 206010024641 Listeriosis Diseases 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 claims description 2
- 206010058780 Meningitis neonatal Diseases 0.000 claims description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 2
- 201000000090 Microsporidiosis Diseases 0.000 claims description 2
- 206010065838 Middle ear inflammation Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- 208000005647 Mumps Diseases 0.000 claims description 2
- 208000006123 Myiasis Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- 208000006816 Neonatal Sepsis Diseases 0.000 claims description 2
- 206010053584 Neonatal pneumonia Diseases 0.000 claims description 2
- 241000243985 Onchocerca volvulus Species 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010033078 Otitis media Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 241000711504 Paramyxoviridae Species 0.000 claims description 2
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 claims description 2
- 241000701945 Parvoviridae Species 0.000 claims description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 2
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims description 2
- 229930195708 Penicillin V Natural products 0.000 claims description 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 2
- 206010034839 Pharyngitis streptococcal Diseases 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 241000223821 Plasmodium malariae Species 0.000 claims description 2
- 241000223810 Plasmodium vivax Species 0.000 claims description 2
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 108010093965 Polymyxin B Proteins 0.000 claims description 2
- 241001631648 Polyomaviridae Species 0.000 claims description 2
- 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 claims description 2
- 241000700625 Poxviridae Species 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000287531 Psittacidae Species 0.000 claims description 2
- 206010037294 Puerperal pyrexia Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 206010037742 Rabies Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 241000702247 Reoviridae Species 0.000 claims description 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 2
- 241000712907 Retroviridae Species 0.000 claims description 2
- 241000606701 Rickettsia Species 0.000 claims description 2
- 229910006069 SO3H Inorganic materials 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 241000447727 Scabies Species 0.000 claims description 2
- 206010039587 Scarlet Fever Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000008582 Staphylococcal Food Poisoning Diseases 0.000 claims description 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
- 206010043376 Tetanus Diseases 0.000 claims description 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 claims description 2
- 241000710924 Togaviridae Species 0.000 claims description 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
- 241000223996 Toxoplasma Species 0.000 claims description 2
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 2
- 208000034784 Tularaemia Diseases 0.000 claims description 2
- 208000037386 Typhoid Diseases 0.000 claims description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 2
- 241000202898 Ureaplasma Species 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 2
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 claims description 2
- 241000700647 Variola virus Species 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 208000000260 Warts Diseases 0.000 claims description 2
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 2
- DLGSOJOOYHWROO-WQLSENKSSA-N [(z)-(1-methyl-2-oxoindol-3-ylidene)amino]thiourea Chemical compound C1=CC=C2N(C)C(=O)\C(=N/NC(N)=S)C2=C1 DLGSOJOOYHWROO-WQLSENKSSA-N 0.000 claims description 2
- GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 claims description 2
- 229960004748 abacavir Drugs 0.000 claims description 2
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 2
- 229950008167 abamectin Drugs 0.000 claims description 2
- 229960000853 abiraterone Drugs 0.000 claims description 2
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims description 2
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 231100000354 acute hepatitis Toxicity 0.000 claims description 2
- 201000005638 acute proliferative glomerulonephritis Diseases 0.000 claims description 2
- 229960001997 adefovir Drugs 0.000 claims description 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 2
- 108700010877 adenoviridae proteins Proteins 0.000 claims description 2
- 229960001686 afatinib Drugs 0.000 claims description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004821 amikacin Drugs 0.000 claims description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 2
- 229960003022 amoxicillin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 2
- 229960001830 amprenavir Drugs 0.000 claims description 2
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 2
- 229960002932 anastrozole Drugs 0.000 claims description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 2
- 230000002001 anti-metastasis Effects 0.000 claims description 2
- 229940068561 atripla Drugs 0.000 claims description 2
- 229960004099 azithromycin Drugs 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229960000997 bicalutamide Drugs 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 201000006824 bubonic plague Diseases 0.000 claims description 2
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 2
- 229960002719 buserelin Drugs 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims description 2
- 229960005361 cefaclor Drugs 0.000 claims description 2
- 229960000603 cefalotin Drugs 0.000 claims description 2
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 claims description 2
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 claims description 2
- 229960003012 cefamandole Drugs 0.000 claims description 2
- 229960001139 cefazolin Drugs 0.000 claims description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 2
- 229940106164 cephalexin Drugs 0.000 claims description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- 229960005091 chloramphenicol Drugs 0.000 claims description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 2
- 208000003167 cholangitis Diseases 0.000 claims description 2
- 208000023652 chronic gastritis Diseases 0.000 claims description 2
- 229960000724 cidofovir Drugs 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960002626 clarithromycin Drugs 0.000 claims description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
- 229940090805 clavulanate Drugs 0.000 claims description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229960004287 clofazimine Drugs 0.000 claims description 2
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 2
- 229960003346 colistin Drugs 0.000 claims description 2
- 229940014461 combivir Drugs 0.000 claims description 2
- 229960005061 crizotinib Drugs 0.000 claims description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 2
- 201000010549 croup Diseases 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960003077 cycloserine Drugs 0.000 claims description 2
- 229960003843 cyproterone Drugs 0.000 claims description 2
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 229960002615 dalfopristin Drugs 0.000 claims description 2
- SUYRLXYYZQTJHF-VMBLUXKRSA-N dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1 SUYRLXYYZQTJHF-VMBLUXKRSA-N 0.000 claims description 2
- 108700028430 dalfopristin Proteins 0.000 claims description 2
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims description 2
- 229960005484 daptomycin Drugs 0.000 claims description 2
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims description 2
- 229960005107 darunavir Drugs 0.000 claims description 2
- 229960002272 degarelix Drugs 0.000 claims description 2
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 claims description 2
- 229960001251 denosumab Drugs 0.000 claims description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 claims description 2
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 229960004100 dirithromycin Drugs 0.000 claims description 2
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 claims description 2
- 229960002542 dolutegravir Drugs 0.000 claims description 2
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 claims description 2
- 229960000895 doripenem Drugs 0.000 claims description 2
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims description 2
- 208000008576 dracunculiasis Diseases 0.000 claims description 2
- 229960000366 emtricitabine Drugs 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 229960002062 enfuvirtide Drugs 0.000 claims description 2
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 claims description 2
- 229960002549 enoxacin Drugs 0.000 claims description 2
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000980 entecavir Drugs 0.000 claims description 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims description 2
- 201000010063 epididymitis Diseases 0.000 claims description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960001904 epirubicin Drugs 0.000 claims description 2
- 229960003649 eribulin Drugs 0.000 claims description 2
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims description 2
- 229960002770 ertapenem Drugs 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 229960000255 exemestane Drugs 0.000 claims description 2
- 229960004396 famciclovir Drugs 0.000 claims description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 2
- 208000006275 fascioliasis Diseases 0.000 claims description 2
- 229960005473 fenbendazole Drugs 0.000 claims description 2
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- CPEUVMUXAHMANV-UHFFFAOYSA-N flubendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=C(F)C=C1 CPEUVMUXAHMANV-UHFFFAOYSA-N 0.000 claims description 2
- 229960004500 flubendazole Drugs 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
- 235000008191 folinic acid Nutrition 0.000 claims description 2
- 239000011672 folinic acid Substances 0.000 claims description 2
- 229960001447 fomivirsen Drugs 0.000 claims description 2
- XCWFZHPEARLXJI-UHFFFAOYSA-N fomivirsen Chemical compound C1C(N2C3=C(C(NC(N)=N3)=O)N=C2)OC(CO)C1OP(O)(=S)OCC1OC(N(C)C(=O)\N=C(\N)C=C)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(N=C(N)C=C2)=O)CC1OP(O)(=S)OCC(C(C1)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)OC1N1C=C(C)C(=O)NC1=O XCWFZHPEARLXJI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003142 fosamprenavir Drugs 0.000 claims description 2
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 claims description 2
- 229960000308 fosfomycin Drugs 0.000 claims description 2
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 claims description 2
- 229960002258 fulvestrant Drugs 0.000 claims description 2
- 229960004675 fusidic acid Drugs 0.000 claims description 2
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 claims description 2
- 229960002963 ganciclovir Drugs 0.000 claims description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229960002913 goserelin Drugs 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 claims description 2
- 229930193320 herbimycin Natural products 0.000 claims description 2
- 229960005236 ibandronic acid Drugs 0.000 claims description 2
- 229960004716 idoxuridine Drugs 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002411 imatinib Drugs 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002182 imipenem Drugs 0.000 claims description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 2
- 229960002751 imiquimod Drugs 0.000 claims description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims description 2
- 229960001936 indinavir Drugs 0.000 claims description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 229960003786 inosine Drugs 0.000 claims description 2
- 229960000318 kanamycin Drugs 0.000 claims description 2
- 229930027917 kanamycin Natural products 0.000 claims description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 2
- 229930182823 kanamycin A Natural products 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 229960002437 lanreotide Drugs 0.000 claims description 2
- 108010021336 lanreotide Proteins 0.000 claims description 2
- 229960004942 lenalidomide Drugs 0.000 claims description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 2
- 229960003881 letrozole Drugs 0.000 claims description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 2
- 229960001691 leucovorin Drugs 0.000 claims description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 2
- 229960004338 leuprorelin Drugs 0.000 claims description 2
- 208000028454 lice infestation Diseases 0.000 claims description 2
- 229960005287 lincomycin Drugs 0.000 claims description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 229960004525 lopinavir Drugs 0.000 claims description 2
- 229960001977 loracarbef Drugs 0.000 claims description 2
- JAPHQRWPEGVNBT-UTUOFQBUSA-M loracarbef anion Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)N)=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-M 0.000 claims description 2
- 229950006243 loviride Drugs 0.000 claims description 2
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 229960004710 maraviroc Drugs 0.000 claims description 2
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 claims description 2
- 229960001786 megestrol Drugs 0.000 claims description 2
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 claims description 2
- XOGYVDXPYVPAAQ-SESJOKTNSA-M meglumine antimoniate Chemical compound O[Sb](=O)=O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO XOGYVDXPYVPAAQ-SESJOKTNSA-M 0.000 claims description 2
- 229940005559 meglumine antimoniate Drugs 0.000 claims description 2
- 229960001728 melarsoprol Drugs 0.000 claims description 2
- 229960004635 mesna Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960003085 meticillin Drugs 0.000 claims description 2
- 229960003152 metisazone Drugs 0.000 claims description 2
- 229960000198 mezlocillin Drugs 0.000 claims description 2
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 208000030194 mouth disease Diseases 0.000 claims description 2
- 208000010805 mumps infectious disease Diseases 0.000 claims description 2
- 229960003128 mupirocin Drugs 0.000 claims description 2
- 229930187697 mupirocin Natural products 0.000 claims description 2
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 2
- 229960000515 nafcillin Drugs 0.000 claims description 2
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims description 2
- 229960000884 nelfinavir Drugs 0.000 claims description 2
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- 229960000808 netilmicin Drugs 0.000 claims description 2
- 229960000689 nevirapine Drugs 0.000 claims description 2
- 229940101771 nexavir Drugs 0.000 claims description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 229940078552 o-xylene Drugs 0.000 claims description 2
- 208000002042 onchocerciasis Diseases 0.000 claims description 2
- 206010030861 ophthalmia neonatorum Diseases 0.000 claims description 2
- 229960001607 oritavancin Drugs 0.000 claims description 2
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 claims description 2
- 108010006945 oritavancin Proteins 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- 229960001019 oxacillin Drugs 0.000 claims description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 2
- 229940046231 pamidronate Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 206010033794 paragonimiasis Diseases 0.000 claims description 2
- 229960001914 paromomycin Drugs 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 claims description 2
- 229960001179 penciclovir Drugs 0.000 claims description 2
- 229940056360 penicillin g Drugs 0.000 claims description 2
- 229940056367 penicillin v Drugs 0.000 claims description 2
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 229960001084 peramivir Drugs 0.000 claims description 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 2
- 229960002292 piperacillin Drugs 0.000 claims description 2
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims description 2
- 229940118768 plasmodium malariae Drugs 0.000 claims description 2
- CSOMAHTTWTVBFL-OFBLZTNGSA-N platensimycin Chemical compound C([C@]1([C@@H]2[C@@H]3C[C@@H]4C[C@@]2(C=CC1=O)C[C@@]4(O3)C)C)CC(=O)NC1=C(O)C=CC(C(O)=O)=C1O CSOMAHTTWTVBFL-OFBLZTNGSA-N 0.000 claims description 2
- CSOMAHTTWTVBFL-UHFFFAOYSA-N platensimycin Natural products O1C2(C)CC3(C=CC4=O)CC2CC1C3C4(C)CCC(=O)NC1=C(O)C=CC(C(O)=O)=C1O CSOMAHTTWTVBFL-UHFFFAOYSA-N 0.000 claims description 2
- 229960000471 pleconaril Drugs 0.000 claims description 2
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 claims description 2
- 201000009430 pneumonic plague Diseases 0.000 claims description 2
- 229960001237 podophyllotoxin Drugs 0.000 claims description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 2
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims description 2
- 229920000024 polymyxin B Polymers 0.000 claims description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 2
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 2
- 229960005266 polymyxin b Drugs 0.000 claims description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims description 2
- 229960000611 pyrimethamine Drugs 0.000 claims description 2
- 229960005442 quinupristin Drugs 0.000 claims description 2
- WTHRRGMBUAHGNI-LCYNINFDSA-N quinupristin Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O WTHRRGMBUAHGNI-LCYNINFDSA-N 0.000 claims description 2
- 108700028429 quinupristin Proteins 0.000 claims description 2
- 229960004432 raltitrexed Drugs 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims description 2
- 229960000329 ribavirin Drugs 0.000 claims description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
- 229960003040 rifaximin Drugs 0.000 claims description 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 201000005404 rubella Diseases 0.000 claims description 2
- 201000003804 salivary gland carcinoma Diseases 0.000 claims description 2
- 229960001852 saquinavir Drugs 0.000 claims description 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000005687 scabies Diseases 0.000 claims description 2
- 201000001223 septic arthritis Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000010153 skin papilloma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- YQDGWZZYGYKDLR-UZVLBLASSA-K sodium stibogluconate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].O1[C@H]([C@H](O)CO)[C@H](O2)[C@H](C([O-])=O)O[Sb]21([O-])O[Sb]1(O)(O[C@H]2C([O-])=O)O[C@H]([C@H](O)CO)[C@@H]2O1 YQDGWZZYGYKDLR-UZVLBLASSA-K 0.000 claims description 2
- 229960001567 sodium stibogluconate Drugs 0.000 claims description 2
- 229960002063 sofosbuvir Drugs 0.000 claims description 2
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 claims description 2
- 201000000539 sparganosis Diseases 0.000 claims description 2
- 229960000268 spectinomycin Drugs 0.000 claims description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims description 2
- 201000002190 staphyloenterotoxemia Diseases 0.000 claims description 2
- 229960001203 stavudine Drugs 0.000 claims description 2
- 229960005256 sulbactam Drugs 0.000 claims description 2
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims description 2
- 229960002673 sulfacetamide Drugs 0.000 claims description 2
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 claims description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004306 sulfadiazine Drugs 0.000 claims description 2
- 229960000973 sulfadimethoxine Drugs 0.000 claims description 2
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 claims description 2
- 229960005158 sulfamethizole Drugs 0.000 claims description 2
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 claims description 2
- 229960005404 sulfamethoxazole Drugs 0.000 claims description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 2
- 229960001940 sulfasalazine Drugs 0.000 claims description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 208000006379 syphilis Diseases 0.000 claims description 2
- 229960002935 telaprevir Drugs 0.000 claims description 2
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 claims description 2
- 108010017101 telaprevir Proteins 0.000 claims description 2
- 229960004964 temozolomide Drugs 0.000 claims description 2
- 229960004556 tenofovir Drugs 0.000 claims description 2
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 claims description 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 2
- 229960003433 thalidomide Drugs 0.000 claims description 2
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 claims description 2
- 229960003053 thiamphenicol Drugs 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 229960004659 ticarcillin Drugs 0.000 claims description 2
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims description 2
- 229960004089 tigecycline Drugs 0.000 claims description 2
- 229960000838 tipranavir Drugs 0.000 claims description 2
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 claims description 2
- 229960000707 tobramycin Drugs 0.000 claims description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 2
- 206010044008 tonsillitis Diseases 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 206010044325 trachoma Diseases 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 229960000323 triclabendazole Drugs 0.000 claims description 2
- 229940086542 triethylamine Drugs 0.000 claims description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001082 trimethoprim Drugs 0.000 claims description 2
- 229940111527 trizivir Drugs 0.000 claims description 2
- 229960000832 tromantadine Drugs 0.000 claims description 2
- UXQDWARBDDDTKG-UHFFFAOYSA-N tromantadine Chemical compound C1C(C2)CC3CC2CC1(NC(=O)COCCN(C)C)C3 UXQDWARBDDDTKG-UHFFFAOYSA-N 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000008297 typhoid fever Diseases 0.000 claims description 2
- 229960004626 umifenovir Drugs 0.000 claims description 2
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 claims description 2
- 229940035893 uracil Drugs 0.000 claims description 2
- 208000000143 urethritis Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229940093257 valacyclovir Drugs 0.000 claims description 2
- 229960002149 valganciclovir Drugs 0.000 claims description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003862 vemurafenib Drugs 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229960000523 zalcitabine Drugs 0.000 claims description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 2
- 229960001028 zanamivir Drugs 0.000 claims description 2
- 229960002555 zidovudine Drugs 0.000 claims description 2
- 229960004276 zoledronic acid Drugs 0.000 claims description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- YSAUAVHXTIETRK-AATRIKPKSA-N pyrantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1 YSAUAVHXTIETRK-AATRIKPKSA-N 0.000 claims 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 2
- 241000186359 Mycobacterium Species 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229960003376 levofloxacin Drugs 0.000 claims 2
- XVDBWWRIXBMVJV-UHFFFAOYSA-N n-[bis(dimethylamino)phosphanyl]-n-methylmethanamine Chemical compound CN(C)P(N(C)C)N(C)C XVDBWWRIXBMVJV-UHFFFAOYSA-N 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims 1
- WYXVGCQNCIEHKQ-UHFFFAOYSA-N 1-carbamimidoyl-1-(2,3,5,6-tetramethylphenyl)guanidine;hydrochloride Chemical compound Cl.CC1=CC(C)=C(C)C(N(C(N)=N)C(N)=N)=C1C WYXVGCQNCIEHKQ-UHFFFAOYSA-N 0.000 claims 1
- JGPNCLKRECLYTO-BJMVGYQFSA-N 1-ethyl-1-[(e)-(5-nitrofuran-2-yl)methylideneamino]urea Chemical compound CCN(C(N)=O)\N=C\C1=CC=C([N+]([O-])=O)O1 JGPNCLKRECLYTO-BJMVGYQFSA-N 0.000 claims 1
- 229940044613 1-propanol Drugs 0.000 claims 1
- 206010006500 Brucellosis Diseases 0.000 claims 1
- 201000006082 Chickenpox Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 241000710781 Flaviviridae Species 0.000 claims 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims 1
- 241000699694 Gerbillinae Species 0.000 claims 1
- 241000222727 Leishmania donovani Species 0.000 claims 1
- 241000214058 Leishmania hertigi Species 0.000 claims 1
- IPWKIXLWTCNBKN-UHFFFAOYSA-N Madelen Chemical compound CC1=NC=C([N+]([O-])=O)N1CC(O)CCl IPWKIXLWTCNBKN-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 201000007981 Reye syndrome Diseases 0.000 claims 1
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 claims 1
- 241000589886 Treponema Species 0.000 claims 1
- 206010046980 Varicella Diseases 0.000 claims 1
- 201000005008 bacterial sepsis Diseases 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 201000006901 congenital syphilis Diseases 0.000 claims 1
- 229960004273 floxacillin Drugs 0.000 claims 1
- 229960003923 gatifloxacin Drugs 0.000 claims 1
- 208000007188 hymenolepiasis Diseases 0.000 claims 1
- 229960005389 moroxydine Drugs 0.000 claims 1
- 229950007888 nifursemizone Drugs 0.000 claims 1
- 229960002313 ornidazole Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960005134 pyrantel Drugs 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 24
- 244000045947 parasite Species 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- KNOPSCVGIXLTNF-UHFFFAOYSA-N 2-(3-hydroxypropyl)benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(N(CCCO)C2=O)=O)=C3C2=CC=CC3=C1 KNOPSCVGIXLTNF-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 208000033211 Ankylostomiasis Diseases 0.000 description 2
- 206010020376 Hookworm infection Diseases 0.000 description 2
- AQXXZDYPVDOQEE-MXDQRGINSA-N Pyrantel pamoate Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 AQXXZDYPVDOQEE-MXDQRGINSA-N 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical class C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960001920 niclosamide Drugs 0.000 description 2
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- XXVLKDRPHSFIIB-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 XXVLKDRPHSFIIB-UHFFFAOYSA-N 0.000 description 1
- IYYCKOCVANJLDB-UHFFFAOYSA-N 2-[3-[(5-aminonaphthalen-1-yl)amino]propyl]benzo[de]isoquinoline-1,3-dione Chemical compound C1=C2C3=C(C=C1)C(=O)N(C(=O)C3=CC=C2)CCCNC1=CC=CC2=C(N)C=CC=C12 IYYCKOCVANJLDB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
- QIXHMCMCFSNKOG-UHFFFAOYSA-N 6492-86-0 Chemical compound O=C1OC(=O)C2=CC=CC3=C2C1=CC=C3N QIXHMCMCFSNKOG-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000006684 Calamidia Species 0.000 description 1
- 241000191796 Calyptosphaeria tropica Species 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000016697 Congenital varicella syndrome Diseases 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 241001122120 Hepeviridae Species 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241001260751 Leishmania equatorensis Species 0.000 description 1
- 241000122142 Leishmania killicki Species 0.000 description 1
- 241000222694 Leishmania naiffi Species 0.000 description 1
- 241000222704 Leishmania peruviana Species 0.000 description 1
- 241000222703 Leishmania shawi Species 0.000 description 1
- 241000222702 Leishmania tarentolae Species 0.000 description 1
- 241000877380 Leishmania turanica Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
- 208000010313 Mansonelliasis Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000003226 Necatoriasis Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000031726 Spotted Fever Group Rickettsiosis Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000006723 Strongylida Infections Diseases 0.000 description 1
- 206010042254 Strongyloidiasis Diseases 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 208000001924 Tungiasis Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 208000005181 Varicella Zoster Virus Infection Diseases 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 208000005067 anisakiasis Diseases 0.000 description 1
- 229940003446 arsphenamine Drugs 0.000 description 1
- VLAXZGHHBIJLAD-UHFFFAOYSA-N arsphenamine Chemical compound [Cl-].[Cl-].C1=C(O)C([NH3+])=CC([As]=[As]C=2C=C([NH3+])C(O)=CC=2)=C1 VLAXZGHHBIJLAD-UHFFFAOYSA-N 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960004828 ceftaroline fosamil Drugs 0.000 description 1
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- VOAZJEPQLGBXGO-SDAWRPRTSA-N ceftobiprole Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(\C=C/4C(N([C@H]5CNCC5)CC\4)=O)CS[C@@H]32)C(O)=O)=O)=N1 VOAZJEPQLGBXGO-SDAWRPRTSA-N 0.000 description 1
- 229950004259 ceftobiprole Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 231100000153 central nervous system (CNS) toxicity Toxicity 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960002488 dalbavancin Drugs 0.000 description 1
- 108700009376 dalbavancin Proteins 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- DYVLXWPZFQQUIU-WGNDVSEMSA-N derquantel Chemical compound O1C(C)(C)C=COC2=C1C=CC1=C2NC[C@]11C(C)(C)[C@@H]2C[C@]3(N(C4)CC[C@@]3(C)O)C(=O)N(C)[C@]42C1 DYVLXWPZFQQUIU-WGNDVSEMSA-N 0.000 description 1
- 229950004278 derquantel Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- ZZTCPWRAHWXWCH-UHFFFAOYSA-N diphenylmethanediamine Chemical compound C=1C=CC=CC=1C(N)(N)C1=CC=CC=C1 ZZTCPWRAHWXWCH-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 230000000282 effect on parasite Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960003170 gemifloxacin Drugs 0.000 description 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000008025 hordeolum Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 108010018844 interferon type III Proteins 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003640 mafenide Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229950001745 mitonafide Drugs 0.000 description 1
- WTERNLDOAPYGJD-SFHVURJKSA-N monepantel Chemical compound C([C@@](C)(NC(=O)C=1C=CC(SC(F)(F)F)=CC=1)C#N)OC1=CC(C#N)=CC=C1C(F)(F)F WTERNLDOAPYGJD-SFHVURJKSA-N 0.000 description 1
- 229950003439 monepantel Drugs 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960002957 praziquantel Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- BTTNOGHPGJANSW-IBGZPJMESA-N radezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C1=CC=C(C=2C=CC(CNCC=3NN=NC=3)=CC=2)C(F)=C1 BTTNOGHPGJANSW-IBGZPJMESA-N 0.000 description 1
- 229950009965 radezolid Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000004284 spotted fever Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Mevcut buluş bisnaftalimidopropil (BNIP) türevi özgün ilaç moleküllerine ve söz konusu özgün ilaç moleküllerinin viral, bakteriyel ve neoplastik hastalıkların tedavisinde kullanımına ve söz konusu özgün moleküllerin viral, bakteriyel ve neoplastik hastalıkların tedavisinde kullanıma uygun bir farmasötik bileşimin hazırlanmasında kullanılmasına ilişkindir.
Description
TARIFNAME
ÖZGÜN BISNAFTALIMIDOPROPIL (BNIP) TÜREVI AKTIF ILAÇ ETKEN
MADDELERI
Mevcut bulus bisnaftalimidopropil (BNlP) türevi özgün ilaç moleküllerine ve söz
konusu özgün ilaç moleküllerinin viral, bakteriyel ve neoplastik hastaliklarin
tedavisinde kullanimina ve söz konusu özgün moleküllerin viral, bakteriyel ve
neoplastik hastaliklarin tedavisinde kullanima uygun bir farmasötik bilesimin
hazirlanmasinda kullanilmasina iliskindir.
Teknigin bilinen durumu
Bakteriyel, viral ve neoplastik hastaliklar dünya popülasyonunun önemli kismini
etkilemekte ve ortalama insan ömrü, yasam kalitesi v.b. parametrelerin
belirlenmesinde önemli rol oynamaktadir. Bu tip hastaliklar hem is gücünde önemli
kayiplara hem de tedavi masrafi nedeniyle ekonomik yüke neden olmaktadir.
Bilinen teknikte bakteriyel, viral, parazitik ve neoplastik hastaliklarin tedavisi için
ajanlar bulunmaktadir ancak yine de etkin tedavi saglayacak özgün ajanlara ihtiyaç
duyulmaktadir.
Özellikle, teknigin bilinen durumunda var olan ilaçlarin sayica az olmasi, uygulama
yöntemlerinin medikal gözlem gerektirmesi ve ciddi yan etkilerinin olmasi bu
hastaligin tedavisini zorlastinnaktadir bu durum yeni etken maddelerin gelistirilmesi
ihtiyacini dogunnaktadir.
Yapilan çalismalar neticesinde, mitonafid gibi naftalimid bilesiklerinin rahim kanseri
ve lösemi üzerinde etkili oldugu bulunmustur, ancak yapilan klinik çalismalarda doz
artisiyla beraber bu ajanlarin merkezi sinir sisteini toksisitesine yol açtigi
görülmüstür.
Teknigin bilinen durumu göz önüne alindiginda, bulus sahipleri bilinen moleküllerin,
örnegin naftalimid türevi moleküllerin, sahip oldugu olumsuz yönleri ortadan kaldiran
ve viral parazitik, neooplastik hastaliklarin tedavisinde kullanima uygun bir molekül
gelistirmeyi amaçlamaktadirlar.
Bulusun bir diger amaci ise bilinen moleküllerin aksine, doz kisitlayici toksisite
problemleri olmayana çözünürlügü ve biyoyararlanimi yüksek yeni moleküller
gelistirmektir.
Bu amaçlar dogrultusunda çalismalar gerçeklestiren bulus sahipleri formül l, formül
ve bakteriyel, Viral, neoplastik hastaliklarin tedavisinde kullanima uygun molekülleri
gelistirmislerdir.
Bulusun Detayli Anlatimi
Mevcut bulus Formül I ile gösterilen moleküllere iliskindir.
Formül 1
n 0 ile 12 arasinda bir dogal sayi olup;
Rl, R2, R3, R4, R5, R6, R7, R3, R9, Riuj RH ve Riz birbirinden bagimsiz olarak;
Cl, F, Br, 1, -OH, -N03 -N02, -COOH, -ORX, -SOZRX, -SOzNHRX, -SOQNRxRy, -CN,
NHCORX, -NHCONHRX, -NHSOng°den olusan bir grubun içerisinden seçilir ve;
RX, RY ve R2 birbirinden bagimsiz olarak; ikameli veya ikamesiz Cl-C12 alkan,
ikameli veya ikamesiz Cl-C12 alken, ikameli veya ikamesiz Cl-C12 alkin, ikameli
veya ikamesiz Cl-C12 primer amin, ikameli veya ikamesiz Cl-Cl2 sekonder amin,
ikameli veya ikamesiz alkol, ikameli veya ikamesiz alkil siyanid, ikameli veya
ikamesiz sülfonamid, ikameli veya ikamesiz Cl-C12 alkyl sülfonil, ikameli veya
ikamesiz C3-C8 sikloalkil, ikameli veya ikamesiz aril, ikameli veya ikamesiz
heteroaril, istege bagli olarak birbirinden bagimsiz olarak 0, S ve N içerisinden
seçilen bir veya daha fazla heteroatom içeren ikameli veya ikamesiz heterosiklik veya
heteroaromatik halkalardan olusan grubun içerisinden seçilir.
Mevcut bulus kapsaminda kullanilan “alkan” terimi düz veya dallanmis doymus
hidrokarbon Zincirlerini ifade etmektedir.
Mevcut bulus kapsaminda kullanilan “alken” terimi en az bir karbon-karbon çift bagi
içeren düz veya dallanmis hidrokarbon Zincirlerini ifade etmektedir.
Mevcut bulus kapsaminda kullanilan “alkin” terimi en az bir karbon-karbon üçlü bagi
içeren düz veya dallanmis hidrokarbon Zincirlerini ifade etmektedir.
Bulusun tercih edilen bir uygulamasinda bulusa uygun moleküller Formül 1 ile
gösterilmekte olup
Formül 1
veya 12 degerini alir;
R1, R2, R3, R4, R5, R6, R7, R3, R9, RIO, RH ve Rlz birbirinden bagimsiz olarak;
CHgCHZCHZCHgCPbCHgCHgCH2CH2CH2CH2CH3, -C(CH3)3, Cl, F, Br, 1, -OH, -
NHSOZCHZCHgN(CH, -
NHCONHCHZCHZSOZNHCH2CH3, - NHCONHCHzCstozN(CH3)2, -
NHCHZCHZSOZNHZ, -NHCHZCHZCstozNHZ, - NHCHgCHgCHzCstogNHg, -
NHCHZCHZSOZNHCH3, -NHCHZCHZSOZN(CH3)25den olusan bir grubun içerisinden
seçilir.
Bulusun tercih edilen bir uygulamasinda Formül 1 ile gösterilen moleküllerde n=0
oldugunda R4 ve R5 bostur.
Bulusun bir diger unsuru Formül H ile gösterilen moleküllerdir;
R14 O R15
Formül 11
-H, -Cl, -F, -Br, -I, RX, -NHZ, -NHRX, -NRXRYv -OH, -NO, -NOz, -COOH, -ORX, -
COORX, -CN içerisinden seçilir ve
RX ve RY birbirinden bagimsiz olarak; ikameli veya ikamesiz C1-C12 alkan, ikameli
veya ikamesiz C1-C12 alken, ikameli veya ikamesiz Cl-Cl2 alkin, ikameli veya
ikamesiz Cl-C12 primer amin, ikameli veya ikamesiz C1-C12 sekonder amin, ikameli
veya ikamesiz alkol, ikameli veya ikamesiz alkil siyanid, ikameli veya ikamesiz
sülfonamid, ikameli veya ikamesiz Cl-ClZ alkyl sülfonil, ikameli veya ikamesiz C3-
C8 sikloalkil, ikameli veya ikamesiz aril, ikameli veya ikamesiz heteroaril, istege
bagli olarak birbirinden bagimsiz olarak 0, S ve N içerisinden seçilen bir veya daha
fazla heteroatom içeren ikameli veya ikamesiz heterosiklik veya heteroaromatik
halkalardan olusan grubun içerisinden seçilir.
Bulusun tercih edilen bir uygulamasinda bulusa uygun moleküller Formül [1 ile
gösterilmekte olup ;
21 R18
Formül 11
Burada Ris. RM. Ris, Rie, Ri7. Ria. Rig, R20, R21 birbirinden bagimsiz olarak;
-H, -Cl, -F, -Br, -I, -NHz, -CH3, C(CH3)2'den olusan bir grubun içerisinden seçilir.
Bulusun bir diger unsuru Formül III ile gösterilen moleküllerdir
Formül lll
-H, -Cl, -F, -Br, -l, RX, -NHZ, -NHRX, -NRxRy, -OH, -COOH, -ORX, -COORX, -CN, -
SO3H, -SO3'Na+, ` , , -NO içerisinden seçilir ve
RX ve RY birbirinden bagimsiz olarak; ikameli veya ikamesiz C1-C12 alkan, ikameli
veya ikamesiz Cl-Cl2 alken, ikameli veya ikamesiz Cl-C12 alkin, ikameli veya
ikamesiz Cl-Cl2 primer amin, ikameli veya ikamesiz Cl-C12 sekonder amin, ikameli
veya ikamesiz alkol, ikameli veya ikamesiz alkil siyanid, ikameli veya ikamesiz
sülfonamid, ikameli veya ikamesiz Cl-C12 alkyl sülfonil, ikameli veya ikamesiz C3-
C8 sikloalkil, ikameli veya ikamesiz aril, ikameli veya ikamesiz heteroaril, istege
bagli olarak birbirinden bagimsiz olarak 0, S ve N içerisinden seçilen bir veya daha
fazla heteroatom içeren ikameli veya ikamesiz heterosiklik veya heteroaromatik
halkalardan olusan grubun içerisinden seçilir.
Bulusun bir diger unsuru Formül [V ile gösterilen moleküllerdir
FormüllV
BuradaRzg;
v 3 ”“3
NH2 NH2 NH2
<> 8& «i
H 1 H J 0 J
M 81& 0
N @1: 0
wmv V\N\O O
H 'den olusan bir grubun içerisinden seçilir.
Bulusun bir diger unsuru Formül V ile gösterilen moleküllerdir
R31 R32
Formül V
-H, -Ci, -F, -Br, -i, RX, -NHZ, -NHRX, -NRxRy, -OH, -NO, -COOH, -ORX, -COORX,
-CN”den olusan bir grubun içerisinden seçilir ve
RX ve Ry birbirinden bagimsiz olarak; ikameli veya ikamesiz C1-C12 alkan, ikameli
veya ikamesiz Cl-C12 alken, ikameli veya ikamesiz Cl-C12 alkin, ikameli veya
ikamesiz C1-C12 primer amin, ikameli veya ikamesiz C1-C12 sekonder amin, ikameli
veya ikamesiz alkol, ikameli veya ikamesiz alkil siyanid, ikameli veya ikamesiz
sülfonamid, ikameli veya ikamesiz Cl-Cl2 alkyl sülfonil, ikameli veya ikamesiz C3-
C8 sikloalkil, ikameli veya ikamesiz aril, ikameli veya ikamesiz heteroaril, istege
bagli olarak birbirinden bagimsiz olarak 0, S ve N içerisinden seçilen bir veya daha
fazla heteroatom içeren ikameli veya ikamesiz heterosiklik veya heteroaromatik
halkalardan olusan grubun içerisinden seçilir.
Bulusun tercih edilen bir uygulamasinda bulusa uygun moleküller Formül V ile
gösterilmekte olup:
Formül V
-H, -NH2, -OCH3, -NO, -Cl, F, 1, Br”dan olusan bir grubun içerisinden seçilir.
Bulusun bir baska unsuru Formül VI ile gösterilen moleküllerdir;
Formül VI
Ci., F, Br, I, -OH_1 -NO, -NOz, -COOH, -ORx, -SOzRx, -SOQNHRx, -SOQNRxRY, -CN,
NHCORX, -NHCONHRX, -NHSOzRX°den olusan bir grubun içerisinden seçilir ve;
RX, RY ve R2 birbirinden bagimsiz olarak; ikaineli veya ikamesiz Cl-C12 alkan,
ikameli veya ikamesiz Cl-C12 alken, ikameli veya ikamesiz Cl-C12 alkin, ikameli
veya ikamesiz Cl-C12 primer amin, ikameli veya ikamesiz Cl-C12 sekonder amin,
ikameli veya ikamesiz alkol, ikameli veya ikamesiz alkil siyanid, ikameli veya
ikamesiz sülfonamid, ikameli veya ikamesiz Cl-Cl2 alkyl sülfonil, ikameli veya
ikamesiz C3-C8 sikloalkil, ikameli veya ikamesiz aril, ikameli veya ikamesiz
heteroaril, istege bagli olarak birbirinden bagimsiz olarak 0, S ve N içerisinden
seçilen bir veya daha fazla heteroatom içeren ikameli veya ikamesiz heterosiklik veya
heteroaromatik halkalardan olusan grubun içerisinden seçilir.
Bulusun tercih edilen bir uygulamasinda bulusa uygun moleküller Formül VI ile
gösterilmekte olup,
Formül VI
-H, -NHz, -CH3, -CHgCHg, -CHgCHzCHg, -C(CH3)3, Cl, F, Br, 1, -OH, -OCHg, -
-COONHCH3, -COON(CH3)2,den olusan bir grubun içerisinden seçilir.
Bulusun bir baska unsuru Formül VII ile gösterilen moleküllerdir;
R47 R50
R R48R49 R
O 46 O O 51
Formül VII
Cl, F, Br, 1, -OH, -N03 -N02, -COOH, -ORX, -SOng, -SOZNHRX, -SOzNRxRy, -CN,
-COORx, -CONHRX, -CONRva, -NHCOCHzRx, -NHCOCHRva, -NHCNHRX, -
NHCORX, -NHCONHRX, -NHSOng°den olusan bir grubun içerisinden seçilir ve;
RX, Ry ve R2 birbirinden bagimsiz olarak; ikameli veya ikamesiz Cl-Cl2 alkan,
ikameli veya ikamesiz Cl-C12 alken, ikameli veya ikamesiz Cl-Cl2 alkin, ikameli
veya ikamesiz Cl-C12 primer amin, ikameli veya ikamesiz Cl-C12 sekonder amin,
ikameli veya ikamesiz alkol, ikameli veya ikamesiz alkil siyanid, ikameli veya
ikamesiz sülfonamid, ikameli veya ikamesiz Cl-Cl2 alkyl sülfonil, ikameli veya
ikamesiz C3-C8 sikloalkil, ikameli veya ikamesiz aril, ikameli veya ikamesiz
heteroaril, istege bagli olarak birbirinden bagimsiz olarak 0, S ve N içerisinden
seçilen bir veya daha fazla heteroatom içeren ikameli veya ikamesiz heterosiklik veya
heteroaromatik halkalardan olusan grubun içerisinden seçilir.
Bulusun tercih edilen bir uygulamasinda bulusa uygun moleküller Formül VII ile
gösterilmekte olup,
R 47R48R49 5 R
O 46 O 0 51
O N/V\ii\l R52
Formül VII
-H, -NHg, -CH3, -CHgCHgH -CHZCHgCH3, -C(CH3)3, Cl, F, Br, 1, -OH, -OCH3, -
-COONHCHL -COON(CH3)2”den olusan bir grubun içerisinden seçilir.
Bulusun tercih edilen bir uygulamasinda formül VIPye uygun moleküllerde R1 I
H7dir.
Bulusun bir baska unsuru Formül VIII ile gösterilen moleküllerdir;
Formül VIII
Cl, F, Br, I, -OH, -NO, -NOz, -COOH, -ORx, -SOzRx, -SO2NHRx, -SOzNRva, -CN,
NHCORX, -NHCONHRX, -NHSOng°den olusan bir grubun içerisinden seçilir ve;
RX, RY ve R2 birbirinden bagimsiz olarak; ikameli veya ikamesiz Cl-C12 alkan,
ikameli veya ikamesiz Cl-C12 alken, ikameli veya ikamesiz Cl-C12 alkin, ikameli
veya ikamesiz Cl-C12 primer amin, ikameli veya ikamesiz Cl-C12 sekonder amin,
ikameli veya ikamesiz alkol, ikameli veya ikamesiz alkil siyanid, ikameli veya
ikamesiz sülfonamid, ikameli veya ikamesiz Cl-C12 alkyl sülfonil, ikameli veya
ikamesiz C3-C8 sikloalkil, ikaineli veya ikamesiz aril, ikameli veya ikamesiz
heteroaril, istege bagli olarak birbirinden bagimsiz olarak 0, S ve N içerisinden
seçilen bir veya daha fazla heteroatom içeren ikameli veya ikamesiz heterosiklik veya
heteroaromatik halkalardan olusan grubun içerisinden seçilir.
Bulusun tercih edilen bir uygulamasinda bulusa uygun moleküller Formül VIII ile
gösterilmekte olup
Formül VIII
-H, -NHZ, -CH3, -CHgCH3, -CHZCHZCH3, -C(CH3)3, Cl, F, Br, 1, -OH, -OCH3, -
-COONHCHg, -COON(CH3)2”den olusan bir grubun içerisinden seçilir.
Bulusun tercih edilen bir uygulamasinda formül VIII”e uygun moleküllerde R1 7
Buna göre mevcut bulus bisnaftalimidopropil türevi moleküllere yönelik olup, bulusa
uygun moleküller;
a) Formül 1;
b) Formül 11;
R14 O R15
O 13 O 0 18
O 0 21 18
c) Formül III;
O R22 O R24
R27
d) Formül IV;
g) Formül VII;
h) Formül VIII;
R45R49
-n 0 ile 12 arasinda bir dogal sayidir,
C1, F, Br, I, -OH, -NO, -NOz, -COOH, -ORx, -SO2Rx, -SO2NHRx, -SOzNRva, -CN,
NHCORX, -NHCONHRX, -NHSOng°den olusan bir grubun içerisinden;
-H, -Cl, -F, -Br, -I, RX, -NHg, -NHRX, -NRxRy, -OH, -NO, -NOz, -COOH, -ORX, -
COORX, -CN içerisinden;
-H, -Cl, -F, -Br, -I, RX, -NHZ, -NHRX, -NRxRy, -OH, -COOH, -ORX, -COORX, -CN, -
SOgH,-SO3"Na+, , , ,-N0içerisinden;
-R29;
NH2 NH2 /
H 1 H 1 H I
NH2 NH2
H 'den olusan bir grubun içerisinden;
-H, -Cl, -F, -Br, -I, RX, -NHZ, -NHRX, -NRXRy, -OH, -NO, -COOH, -ORX, -COORX,
-CN,den olusan bir grubun içerisinden;
RX, RY ve R2 ise birbirinden bagimsiz olarak; ikameli veya ikamesiz C1-C12 alkan,
ikameli veya ikamesiz C1-C12 alken, ikaineli veya ikamesiz C1-C12 alkin, ikaineli
veya ikamesiz C1-C12 primer amin, ikaineli veya ikamesiz C1-C12 sekonder amin,
ikameli veya ikamesiz alkol, ikameli veya ikamesiz alkil siyanid, ikameli veya
ikamesiz sülfonamid, ikameli veya ikamesiz C1-C12 alkyl sülfonil, ikameli veya
ikamesiz C3-C8 sikloalkil, ikaineli veya ikamesiz aril, ikaineli veya ikamesiz
heteroaril, istege bagli olarak birbirinden bagimsiz olarak 0, S ve N içerisinden
seçilen bir veya daha fazla heteroatom içeren ikameli veya ikamesiz heterosiklik veya
heteroaromatik halkalardan olusan grubun içerisinden seçilir.
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 1 ile
gösterilmektedir;
Formül 1
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 2 ile
gösterilmektedir;
Formül.?
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 3 ile
gösterilmektedir;
Formül 3
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 4 ile
gösterilmektedir;
Formül 4
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 5 ile
gösterilmektedir;
Formül 5
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 6 ile
gösterilmektedir;
F0rmül6
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 7 ile
gösterilmektedir;
Formül 7Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 8 ile
gösterilmektedir;
Formül 8
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 9 ile
Formül 9
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 10 ile
Formül 10
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Formül l°e uygun molekül Formül 11 ile
gösterilmektedir;
Formül 11
Bulusun tercih edilen bir uygulamasinda Formül Pe uygun molekül Formül 12 ile
gösterilmektedir;
Formül 12
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 13 ile
gösterilmektedir;
Formül 13
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 14 ile
gösterilmektedir;
Formül 14
Bulusun tercih edilen bir uygulamasinda Formül lie uygun molekül Formül 15 ile
gösterilmektedir;
Formül 15
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 16 ile
gösterilmektedir;
Formül 1 6
Bulusun tercih edilen bir uygulamasinda Formül Pe uygun molekül Formül 17 ile
gösterilmektedir;
Formüll?
Bulusun tercih edilen bir uygulamasinda Formül Pe uygun molekül Formül 18 ile
gösterilmektedir;
Formül 18
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 19 ile
gösterilmektedir;
Formü119
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 20 ile
gösterilmektedir;
Formül 20
Bulusun tercih edilen bir uygulamasinda Formül l”e uygun molekül Formül 21 ile
Formül 21
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 22 ile
gösterilmektedir;
FormÜIZZ
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 23 ile
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Forinül Fe uygun molekül Formül 24 ile
gösterilmektedir;
Formül 24
Bulusun tercih edilen bir uygulamasinda Formül l”e uygun molekül Formül 25 ile
gösterilmektedir;
Formül 25
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 26 ile
gösterilmektedir;
Formü126
Bulusun tercih edilen bir uygulamasinda Formül l”e uygun molekül Formül 27' ile
gösterilmektedir;
Formül 27
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 28 ile
gösterilmektedir;
Formül 28
Bulusun tercih edilen bir uygulamasinda Formül Pe uygun molekül Formül 29 ile
Formül 29
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Formül Ve uygun molekül Formül 30 ile
Formül 30
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 31 ile
1 5 gösterilmektedir;
Formül 31
Bulusun tercih edilen bir uygulamasinda Formül Pe uygun molekül Formül 32 ile
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 33 ile
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 34 ile
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Formül l”e uygun molekül Formül 35 ile
gösterilmektedir;
Formül 35
Bulusun tercih edilen bir uygulamasinda Formül Pe uygun molekül Formül 36 ile
gösterilmektedir;
F0rmül36
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 37 ile
gösterilmektedir;
Formül 37
Bulusun tercih edilen bir uygulamasinda Formül l”e uygun molekül Formül 38 ile
gösterilmektedir;
Formül 38
Bulusun tercih edilen bir uygulamasinda Formül l”e uygun molekül Formül 39 ile
gösterilmektedir;
Formül 39
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 40 ile
gösterilmektedir;
Formül 40
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 41 ile
gösterilmektedir;
Formül 41
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 42 ile
gösterilmektedir;
Formül 42
Bulusun tercih edilen bir uygulamasinda Formül l”e uygun molekül Formül 43 ile
gösterilmektedir;
Formül 43
Bulusun tercih edilen bir uygulamasinda Formül l”e uygun molekül Formül 44 ile
gösterilmektedir;
Formül 44
Bulusun tercih edilen bir uygulamasinda Formül Pe uygun molekül Formül 45 ile
gösterilmektedir;
Formül 45
Bulusun tercih edilen bir uygulamasinda Formül Fe uygun molekül Formül 46 ile
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Formül Pe uygun molekül Formül 47 ile
gösterilmektedir;
Formül 47
Bulusun tercih edilen bir uygulamasinda Formül IFye uygun molekül Formül 48 ile
gösterilmektedir;
Formül 48
Bulusun tercih edilen bir uygulamasinda Formül II”ye uygun molekül Formül 49 ile
gösterilmektedir;
Formül 49
Bulusun tercih edilen bir uygulamasinda Formül II”ye uygun molekül Formül 50 ile
gösterilmektedir;
Formül 50
Bulusun tercih edilen bir uygulamasinda Formül ll“ye uygun molekül Formül 51 ile
gösterilmektedir;
Formül 51
Bulusun tercih edilen bir uygulamasinda Formül ll“ye uygun molekül Formül 52 ile
gösterilmektedir;
Formül 52
Bulusun tercih edilen bir uygulamasinda Formül ll“ye uygun molekül Formül 53 ile
gösterilmektedir;
Formül 53
Bulusun tercih edilen bir uygulamasinda Formül ll”ye uygun molekül Formül 54 ile
gösterilmektedir;
Formül 54
Bulusun tercih edilen bir uygulamasinda F orinül lllle uygun molekül Formül 55 ile
gösterilmektedir;
Formül 55
Bulusun tercih edilen bir uygulamasinda Formül IIPe uygun molekül Formül 56 ile
gösterilmektedir;
Formül 56
Bulusun tercih edilen bir uygulamasinda Formül lll,e uygun molekül Formül 57 ile
gösterilmektedir;
Formül 57
Bulusun tercih edilen bir uygulamasinda Formül III°e uygun molekül Formül 58 ile
gösterilmektedir;
Formül 58
Bulusun tercih edilen bir uygulamasinda Forinül lllle uygun molekül Formül 59 ile
gösterilmektedir;
O 0 *Na'Ogs SOgNa*
Formül 59
Bulusun tercih edilen bir uygulainasinda F orinül lll°e uygun molekül Formül 60 ile
gösterilmektedir;
Formül 60
Bulusun tercih edilen bir uygulamasinda Formül HPe uygun molekül Formül 61 ile
gösterilmektedir;
Formül 61
Bulusun tercih edilen bir uygulamasinda Formül Illle uygun molekül Formül 62 ile
gösterilmektedir;
Formül 62
Bulusun tercih edilen bir uygulamasinda Formül lV”e uygun molekül Formül 63 ile
gösterilmektedir;
Formül 63
Bulusun tercih edilen bir uygulamasinda Formül Ivle uygun molekül Formül 64 ile
gösterilmektedir;
Formül 64
Bulusun tercih edilen bir uygulamasinda Formül IV`e uygun molekül Formül 65 ile
gösterilmektedir;
Formül 65
Bulusun tercih edilen bir uygulamasinda Formül IV`e uygun molekül Formül 66 ile
gösterilmektedir;
Formül 66
Bulusun tercih edilen bir uygulamasinda Formül IV7e uygun molekül Formül 67 ile
gösterilmektedir;
Formül 67
Bulusun tercih edilen bir uygulamasinda Formül IV”e uygun molekül Formül 68 ile
gösterilmektedir;
Formül 68
Bulusun tercih edilen bir uygulamasinda Formül IV”e uygun molekül Formül 69 ile
gösterilmektedir;
Formül 69
Bulusun tercih edilen bir uygulamasinda Formül IVle uygun molekül F orinül 70 ile
gösterilmektedir;
Formül70
Bulusun tercih edilen bir uygulamasinda Formül IVSe uygun molekül Formül 71 ile
gösterilmektedir;
Formül 71
Bulusun tercih edilen bir uygulamasinda Formül IV,e uygun molekül Formül 72 ile
gösterilmektedir;
Formül72
Bulusun tercih edilen bir uygulamasinda Formül IVSe uygun molekül Formül 73 ile
gösterilmektedir;
Formül 73
Bulusun tercih edilen bir uygulamasinda Formül lV”e uygun molekül Formül 74 ile
gösterilmektedir;
Formül 74
Bulusun tercih edilen bir uygulamasinda Formül lV*e uygun molekül Formül 75 ile
gösterilmektedir;
Formül 75
Bulusun tercih edilen bir uygulamasinda Formül IV”e uygun molekül Formül 76 ile
gösterilmektedir;
Formül 76
Bulusun tercih edilen bir uygulamasinda Formül lV”e uygun molekül Formül 77 ile
gösterilmektedir;
Formül 77
Bulusun tercih edilen bir uygulainasinda Formül IV”e uygun molekül Formül 78 ile
gösterilmektedir;
Formül 78
Bulusun tercih edilen bir uygulamasinda Formül IV`e uygun molekül Formül 79 ile
gösterilmektedir;
Formül 79
Bulusun tercih edilen bir uygulamasinda Formül IV,e uygun molekül Formül 80 ile
gösterilmektedir;
Formül 80
Bulusun tercih edilen bir uygulamasinda Formül IVle uygun molekül Formül 81 ile
gösterilmektedir;
Formül 81
Bulusun tercih edilen bir uygulamasinda Formül IVle uygun molekül Formül 82 ile
Formül 82
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Formül IVSe uygun molekül Formül 83 ile
gösterilmektedir;
Formül 83
Bulusun tercih edilen bir uygulamasinda Formül lV”e uygun molekül Formül 84 ile
gösterilmektedir;
Formül 84
Bulusun tercih edilen bir uygulamasinda Formül lV”e uygun molekül Formül 85 ile
gösterilmektedir;
Formül 85
Bulusun tercih edilen bir uygulamasinda Formül IV”e uygun molekül Formül 86 ile
gösterilmektedir;
Formül 86
Bulusun tercih edilen bir uygulamasinda Formül V,e uygun molekül Formül 87 ile
gösterilmektedir;
Formül 87
Bulusun tercih edilen bir uygulamasinda Formül V”e uygun molekül Forinül 88 ile
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Formül V`e uygun molekül Formül 89 ile
gösterilmektedir;
Formül 89
Bulusun tercih edilen bir uygulamasinda Formül ve uygun molekül Formül 90 ile
gösterilmektedir;
Formül 90
Bulusun tercih edilen bir uygulamasinda Formül V'e uygun molekül Formül 91 ile
gösterilmektedir;
Formül 91
Bulusun tercih edilen bir uygulamasinda Formül V”e uygun molekül Formül 92 ile
gösterilmektedir;
Formül 92
Bulusun tercih edilen bir uygulamasinda Formül VPya uygun molekül Formül 93 ile
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda F ormül Vllya uygun molekül Formül 94 ile
gösterilmektedir;
Formül 94
Bulusun tercih edilen bir uygulamasinda Formül VIPye uygun molekül Formül 95 ile
gösterilmektedir;
Formül 95
Bulusun tercih edilen bir uygulamasinda Formül VII'ye uygun molekül Formül 96 ile
gösterilmektedir;
Formül 96
Bulusun tercih edilen bir uygulamasinda Formül VHPe uygun molekül Formül 97' ile
gösterilmektedir;
Bulusun tercih edilen bir uygulamasinda Formül Vlll°e uygun molekül Formül 98 ile
gösterilmektedir;
Formül 98
Bulusun tercih edilen bir uygulamasinda Formül Vlll°e uygun molekül Formül 99 ile
gösterilmektedir;
Formül 99
Yukarida kimyasal yapilari ve spesifik kimyasal isimlendirmeleri verilen formül 1-99
ile gösterilen bulusa uygun moleküller bulusu açiklamak amaçli verilmis olup bulus
kapsami bu moleküllerle sinirlandirilmamaktadir.
Bulusa uygun Formül I, Formül II, Formül III, Formül IV, Formül V, Formül VI,
Formül VII, Formül VIII ile gösterilen etken maddelerin elde edilmesinde
kullanilabilecek bir metot;
a) Formül X ile gösterilen maddenin çözücü, tercihen diklorometan, varliginda
para-metil sülfonil klorid ile reaksiyona sokulmasi,
Formül X
b) Olusan ara ürünün (Formül Y) çözücü, tercihen asetonitril, varliginda NaI ile
karistirilmasi ve bu karisima çözücü, tercihen asetonitril içerisinde, diamino
bilesigi ile K2C03 çözeltisi ilave edilmesi
Formül Y
c) Son ürünün reaksiyon karisimindan izole edilmesi adimlarini içerrnektedir.
Burada kullanilan “çözücü” terimi, reaksiyon esnasinda kullanilan reaktiflerin
çözünmesini saglayacak herhangi bir organik solventi ifade etmektedir.
Söz konusu organik solvent asetik asit, aseton, asetonitril, benzeri, l-butanol, 2-
butanol, 2-butanon, t-butil alkol, karbon tetraklorür, klorobenzen, kloroform,
siklohekzan, 1,2-diklor0etan, dietilen glikol, dietileter, dietilen glikol dimetil eter, 1,2-
dimetoksietan (DME), dimetilformamid (DMF), dimetilsülfoksit (DMSO), 1,4-
dioksan, etanol, etil asetat, etilen glikol, gliserin, heptan, hekzametilfosforamid
(HMPA), hekzainetilfosforus triamid (HMPT), hekzan, metanol, metilt-bütil eter
(MTBE), metilen klorür (DCM), N-metil-Z-pirolidon (NMP), nitrometan, pentan,
petrol eteri, l-propanol, 2-propanol, piridin, tetrahidrofuran (THF), tolüen, trietil
amin, su, o-ksilen, m-ksilen, p-ksilen'den olusan bir grubun içerisinden seçilebilir.
Metot I ile gösterilen yöntem 0-90 ÜC araliginda bir sicaklikta tercihen veya 25-80 UC
araliginda bir sicaklikta gerçeklestirilebilirler. Metot içerisindeki her bir adim bir
digerinden farkli bir sicaklikta gerçeklestirilebilir.
Bulusa uygun yöntemlerle elde edilen ürünler,filtrasy0n, santrifîij, ekstrasyon,
kristalizasyon, rekristalizasyon, kromatografî, distilasyon gibi yöntemlerle
saflastirilabilir.
Burada bahsedilen kromatografi yöntemi; kolon kromatografisi, gaz kromatografisi,
sivi kromatografisi, ters fazli sivi kromatografisi içerisinden seçilebilir.
Bulus bir diger açidan Formül I, Formül ll, Formül III, Formül IV, Formül V, Formül
VI, Formül VII, Formül VIII ile gösterilen bilesiklerin ilaç olarak kullanimini
açiklamaktadir.
Mevcut bulus bir açidan bulusa uygun Formül I, Formül II, Formül III, Formül IV,
Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen moleküllerin parazitik
hastaliklarin tedavisinde kullanimina iliskindir.
Burada kullanilan “parazitik hastaliklar” ifadesi bir parazitin neden oldugu veya
bulastirdigi hastaliklari ifade etmektedir.
Burada bahsedilen parazitik hastaliklar Sistozomiyaz, opistorsiyaz, klonorkiyaz,
dikrosölyoz, fasioliyazis, paragonimiyaz, fasiolopsiyaz, ekinokokiyaz, tenyazis,
sistiserkoz, difilobotrtyaz, sparganoz, himenolepiyaz, drakunkuliyaz, onkoserkiyazis,
filaryaz, elefantiyazis, mansonelloz, trisinelozis, ankilostomiyaz, nekatoryaz,
ankilostomyazis, askardiyoz, strongiloidiyaz, trisüriyaz, enterobiyazis, anisakiyaz,
helmintiyazis, trikostronjiloz, anjiyostrongiloz, gnatostomiyaz, anjiyostrongiloz,
singamiyaz, hirudiniyaz, akantosefallyaz, gongilonemiyaz, metastrongilyaz, telaziyaz,
pediküloz, pithiriyaz, skabiyez, miyaz, tungiyaz, trombikuloz, skarabiazis,
hirudiniyaz, linguatuloz, porosefaliyaz, leishmania, trypanosomiasis, plazmodyum
falsiparum7un neden oldugu malarya, plazmodyum Vivaxün neden oldugu malarya,
plazmodyum malariae7nin neden oldugu malarya, chagas hastaligi, toksoplazma,
pnömosistoz, babeziyoz, piroplazmoz, akantamebiyaz, naegleriyaz ve/veya
mikrosporidioz olabilir.
Bulusun tercih edilen bir uygulamasinda formül I, Formül II, Formül III, Formül IV,
Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen moleküller
Leishmaniasis tedavisinde kullanima uygun bir ilacin içerisinde kullanilir.
Bulus, tercihen Formül I, Formül II, Formül III, Forinül IV, Formül V, Formül VI,
Formül VII, Formül VIII ile gösterilen moleküllerin leishmaniasis tedavisinde
kullanimina iliskindir. Burada bahsi geçen Leishmaniasis hastaligi kütanöz,
mukokütanöz veya viseral Leishmaniasis olabilir.
Bulus bir diger açidan L. Arabica, L. archibaldi, L. aristedesi, L. braziliensis, L.
chagasi, L. colombiensis,L. Deanei, L. donovam', L. enrietii, L. equatorensis, L.
forartinii, L. garnhamz', L. gerbii', Lguyanensi's, L. herreri, L. herrigi, L. infantum, L.
killicki', L. lainsoni, L. major, L. Mexicana, L. naiffî, L. panamensis, L. peruviana, L.
pifanoi, L. shawi, L. tarentolae, L. tropica, L. turanica, L. venezuelensi's türü
parazitlerin neden oldugu enfeksiyonel hastaliklarin tedaivisinde mevcut bulusa
uygun Formül I, Formül II, Formül III, Formül IV, Formül V, Formül VI, Formül VII,
Forinül VIII ile gösterilen moleküllerin kullaniinina iliskindir.
Mevcut bulus bir açidan bulusa uygun Formül I, Formül II, Formül III, Formül IV,
Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen moleküllerin bakteriyel
hastaliklarin tedavisinde kullanimina iliskindir.
Burada kullanilan “bakteriyel hastaliklar” ifadesi patojenik balterilein neden oldugu
enfeksiyonlardan kaynaklanan hastaliklari ifade etmektedir.
Mevcut bulus kapsamindaki bakterilyel hastaliklar basili, bartonella, bordetella,
borrelia, brusella, kampilobakter, kalamidya, kalamidotila, klostridyum,
korinebakteryum, enterokokkus, eserya, fransiyella, hemofilus, helikobakter,
lejyonella, leptospira, listeria, inikobakteryuin, mikoplazma, nisserya, psödomonas,
riketsiya, salinonella, sigella, stafilokokkus, streptokokkus, treponeina, üreplazma,
vibrio, yersinia, ana gruplarina mensup bakteriler nedeniyle olusan herhangi bir
bakteriyel hastalik olabilir.
Söz konusu bakteriyel hastaliklar, ömegin bubonic veba, pnömonik veba, kolera,
sifilis, konjenital sitilis, post streptokoksik glomerulonefrit, lohusa hummasi,
impetigo, yilancik, atesli romatizma, kizil, streptokokkal faranjit, sepsis, akut
bakteriyel pnömoni, menenjit, orta kulak iltihabi, endometrit, neonatal sepsis,
neonatal menenjit, neonatal pnömoni, sistit, osteomiyelit, toksik sok sendromu,
stafilokokkal gida zehirlenmesi, sigelloz, salmonella, paratifo, tifo, kayalik daglar
lekeli hummasi, idrar yolu enfeksiyonlari, kornea enfeksiyonlari, pnömoni,
endokardit, menenjit, gnore, pelvik enflamatuar hastaligi, tüberküloz, cüzzam,
listeriyoz, leptospiroz, lejyoner hastaligi, peptik ülser, üst solunum yolu
enfeksiyonlari, kronik gastrit, bronsit, septik artrit, tularemia, kanli diyare, idrar yolu
enfeksiyonlari, endokardit, safra yolu enfeksiyonlari, difteri, tetanoz, papagan
hummasi, trachoma, neonatal konjuktivit, üretrit, epididimit, prostatit,
lenfogranülomatoz, atipik pnömoni, Guillain-Barre Sendromu, broselloz, malta
hummasi, lyme hastaligi olabilir.
Mevcut bulus bir açidan bulusa uygun Formül 1, Formül II, Formül III, Formül IV,
Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen moleküllerin viral
hastaliklarin tedavisinde kullanimina iliskindir.
Mevcut bulus kapsaminda kullanilan “viral hastaliklar” ifadesi patojenik virüslerin ve
bulasici virus partiküllerin (viron) kendilerini hürelere baglayip hücrelere giris
yapmasiyla olusan hastaliklarin tainainini ifade etmektedir.
Bahsedilen viral hastaliklar adenoviridae, herpesviridae, papillomaviridae,
polyomaviridae, poxviridae, heradnaviridae, parvoviridae, astroviridae, caliciviridae,
picornaviridae, coronaviridae, Ilaviviridae, togaviridae, hepeviridae, retroviridae,
ortomiksoviridae, arenaviridae, bunyaviridae, filoviridae, paramiksoviridae,
rabdoviridae, reoviridae ana ailelerine mensup olan herhangi bir virüsün neden oldugu
bir hastalik olabilir.
Söz konusu viral hastaliklara ait özel örnekler, gasteroentirit, keratokonjuktivit,
farenjit, krup, pnömoni, sistit, el-ayak-agiz hastaligi, pleurodnia, septik menenjit,
perikadit, miyokardit, Burkitt°e Lenfoma, Hodgin”s lenfoma, nasafaranjiyel karsinom,
akut hepatit, kronik hepatit, hepatic siroz, hepatoselüler karsinom, tonsilit, sitomegalik
inklüzyon hastaligi, Kaposi sarkomu, castleman hastaligi, influenza, kizamik, reye
sendromu, kabakulak, anogenital sigil, poliomiyellit, kuduz, konjenital rubella,
kizamikçik, çiçek hastaligi, zona, konjenital su çiçegi sendromuolabilir.
Mevcut bulus bir açidan bulusa uygun Formül I, Formül II, Formül III, Formül IV,
Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen moleküllerin neoplastik
hastaliklarin tedavisinde kullanimina iliskindir.
Mevcut bulus kapsaminda kullanilan “neoplastik hastaliklar” ifadesi habis (malign)
tümörlere veya kontrolsüz hücre büyümesi ile karakterize olan bir fizyolojik duruma,
örnegin kanser hastaligina isaret eder. Bulus kapsaminda “neoplastik hastalik” ve
karsinoma, lenfoma, blastoma sarkoma ve lösemiyi içermekte olup bunlarla sinirli
degildir.
Karsinoma, burada kullanildigi sekliyle, epitel hücrelerden olusan bir kanser türünü
ifade etmektedir.
Lenfoma, burada kullanildigi sekliyle, lenfositlerden gelisen bir kanser türünü
anlatmaktadir.
Blastoma, burada kullanildigi sekliyle, blast hücre adiyla da bilinen öncü hücrelerden
gelisen bir kanser türünü anlatmaktadir.
Sarkoma, burada kullanildigi sekliyle, mezenkimal kökenli degismis hücrelerden
kaynaklanan kanser türünü anlatmaktadir.
Lösemi, burada kullanildigi sekliyle, kemik iliginde baslayan ve yüksek sayida
anormal akyuvar hücresi olusumuna neden olan kanser türünü ifade etmektedir.
Kanser türlerine ait daha özel örnekler meme kanseri, prostat kanseri, kolorektal
kanser, deri kanseri, küçük hücreli akciger kanseri, küçük hücreli olmayan akciger
kanseri, mezotelyom, gastrointestinal kanser, pankreas kanseri, gliyoblastom, vulva
kanseri, rahim agzi kanseri, endometriyal karsinom, yumurtalik kanseri, karaciger
kanseri, hepatom, mesane kanseri, böbrek kanseri, tükürük bezi karsinomu, tiroid
kanseri ve çesitli bas ve boyun kanserlerini içerir.
Bulus ayrica etken madde olarak bulusa uygun Formül I, Formül II, Formül III,
Formül IV, Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen bilesikleri
içeren bir farmasötik bilesime iliskindir.
Söz konusu farrnasötik bilesimler Formül I, Formül II, Formül III, Formül IV, Formül
V, Formül VI, Formül VII, Formül VIII ile gösterilen bilesiklere ilave olarak en az bir
diger etken madde içerebilir,
Mevcut bulusun bir baska uygulamasinda Formül I, Formül II, Formül III, Formül IV,
Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen bulusa uygun bilesikler
diger antiparazitik, antibakteriyel, antiviral, antineoplastik ve/veya sitotoksik ve/veya
antimetastatik etki gösteren bilinen aktif bilesiklerle veya bunlarin ikili/üçlü
kombinasyonlariyla beraber kullanilabilir. Ikinci etken madde Formül I, Fom1ü1 II,
Formül III, Formül IV, Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen
bilesiklerle beraber formüle edilebilecegi gibi Formül I, Formül II, Formül III, Formül
formüle edilip beraber kullanima uygun paketlerde satisa sunulabilir.
Bulusun tercih edilen bir uygulamasinda Formül I, Formül II, Formül III, Formül IV,
Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen bilesikler en az bir adet
antibakteriyel etki gösteren aktif bilesikle kombine edilir.
Formül VIII ile gösterilen bilesiklerle kombine olarak kullanilabilecek antibakteriyel
etki gösteren aktif` bilesikler amikasin, gentamisin, kanamisin, neomisin, netilmisin,
tobramisin, paromisin, streptomisin, spektinomisin, geldanamisin, herbimisin,
rifaksimin, lorakarbef, ertapenem, doripenem, imipenem, meropenem, sefadroksil,
sefazolin, sefalotin, sefaleksin, sefaklor, sefamandol, sefoksitin, sefprozil, sefuroksim,
sefiksim, sefdinir, sefditoren, sefoperazon, sefotaksim, sefpodoksim, seftazidim,
seftibüten, seftizoksim, sefepim, seftarolin fosamil, seftobiprol, teikoplanin,
vankomisin, televansin, dalbavansin, oritavansin, clindamisin, linkomisin, daptomisin,
azitromisin, klaritromisin, diritromisin, eritromisin, roksitromisin, troleandomisin,
telitromisin, spiramisin, aztreonam, furazolidon, nitrofurantoin, linezolid, posizolid,
radezolid, torezolid, amoksisilin, ampisilin, azlosilin, karbenisilin, kloksasilin,
dikloksasilin, Ilukloksasilin, mezlosilin, metisilin, nafsilin, okzasilin, penisilin G,
penisilin V, piperasilin, temosilin, tikarsilin, klavulanat, sulbaktam, tazobaktam,
basitrasin, kolistin, polimiksin B, siproiloksasin, enoksasin, gatiIloksasin,
gemifloksasin, levoIloksasin, lomefloksasin, moksifloksasin, nalidinik asit,
norfloksasin, ofloksasin, trovafloksasin, grepafloksasin, sparfloksasin, temaIloksasin,
mafenid, sulfasetamid, sulfadiazin, sülfadimetoksin, sülfametizol, sülfametoksazol,
sulfanilimid, sülfasalazin, Sülfisoksazol, trometoprim, demeklosiklin, doksisiklin,
minosiklin, oksitetrasiklin, tetrasiklin, klofazimin, dapson, kapreomisin, sikloserin,
etambutol, isoniyazid, pyrazinamid, rifampisin, rifabutin, rifapentin, streptomisin,
arsfenamin, kloramfenikol, fosfomisin, fusidik asit, metronidazol, mupirosin,
platensimisin, kinupristin, dalfopristin, tiamfenikol, tigesiklin, tinidazol, trimetoprim”i
içeren grubun içerisinden veya burada sayilan ajanlarin ikili veya üçlü
kombinasyonlari içerisinden seçilebilir.
Bulusun tercih edilen bir diger uygulamasinda Formül I, Formül II, Formül III,
Formül IV, Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen bilesikler en
az bir adet antiviral etki gösteren aktif bilesikle kombine edilir.
Formül VIII ile gösterilen bilesiklerle kombine olarak kullanilabilecek antiviral etki
gösteren aktif bilesikler abakavir, asiklovir, adefovir, amantadin, amprenavir,
ampligen, arbidol, atazanavir, atripla, balavir, sidofovir, kombivir, dolutegravir,
darunavir, delavirdin, didanosin, dokosanol, eduksudin, efavirenz, emtrisitabin,
enfuvirtid, entekavir, ekoliver, famsiklovir, fomivirsen, fosamprenavir, foskarnet,
fosfonet, gansiklovir, ibasitabin, imunovir, idoksuridin, imikuimod, indinavir, inosin,
interferon tip I, interferon tip II, interferon tip III, interferon, lamivudin, lopinavir,
lovirid, maravirok, moroksidinj metisazon, nelfinavir, nevirapin, neksavir,
nitazoksanid, novir, oseltamivir, peginterferon alfa-Za, pensiklovir, peramivir,
plekonaril, podofilotoksin, proteaz inhibitörü, nükleosit analoglari, ralgetavir,
ribavirin, rimantadin, ritonavir, piramidin, saquinavir, sofosbuvir, stavudin, telaprevir,
tenofovir, tipranavir, trifliridine, trizivir, tromantadin, trovada, valasiklovir,
valgansiklovir, vidarabin, Viramidin, zalsitabin, zanamivir, zidovudinî içeren grubun
içerisinden veya burada sayilan ajanlarin ikili veya üçlü kombinasyonlari içerisinden
seçilebilir.
Bulusun tercih edilen bir diger uygulamasinda Formül I, Formül II, Formül III,
Formül IV, Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen bilesikler en
az bir adet antiparazitik etki gösteren aktif bilesikle kombine edilir.
Formül I ile gösterilen bilesiklerle kombine olarak kullanilabilecek antiparazitik etki
gösteren aktif bilesikler nitazoksanit, melarsoprol, eflornitin, metronidazol, tinidazol,
miltefosin, mebendazol, pirantel pamoat, tiyabendazol, dietilkarbamazin, ivermektin,
niklosamid, prazikuantel, albendazol, rifampin, amfoterisin B, fumagillin,
furazolidon, nifursemizon, nitaksozanid, omidazol, paramomisin sülfat, pentamidin,
pirimetamine, tinidazol, albendazol, mebendazol, tiyabendazol, fenbendazol,
triklabendazol, flubendazol, abamektin, dietilkarbamazin, ivermektin, suramin,
pirantel pamoat, levamisol, niklosamid, nitasokzanid, oksiklonazd, monepantel,
derquantel, amfoterisin B, üre stibamin, sodyum stiboglukonat, meglumin antimoniat,
paromomisin, miltefosin, Ilukonazol, pentamidin”den olusan bir grubun içerisinden
veya bunlarin ikili, üçlü kombinasyonlari içerisinden seçilebilir.
Bulusun tercih edilen bir diger uygulamasinda Formül I, Formül II, Formül III,
Formül IV, Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen bilesikler en
az bir adet antineoplastik etki gösteren aktif bilesikle kombine edilir.
Formül VIII ile gösterilen bilesiklerle kombine olarak kullanilabilecek antineoplastik
etki gösteren aktif bilesikler siklofosfamid, ifosfamid, temozolomid, kapesitabin, 5-
Iloro urasil, metotreksat, gemsitabin, pemetrekset, mitomisin, bleomisin, epirubisin,
doksorubisin, etoposit, paklitaksel, irinotekan, dosetaksel, vinkristin, karboplatin,
cisplatin, okzaliplatin, bevacizumab, setuksimab, gefitinib, imatinib, trastuzumab,
denosumab, rituksimab, sunitinib, zoledronat, abirateron, anastrozol, bikalutamid,
eksemestan, goserelin, medroksiprogesteron, oktreotid, tamoksifen, bendamustin,
karmustin, klorambusil, lomustin, melfalan, prokarbazin, streptozosin, fludarabin,
raltitrexed, aktinomisin D, daktinomisin, doksorubisin, mitoksantron, eribulin,
topotekan, vinblastin, vinorelbin, afatinib, ailibersept, krizotinib, dabrafenib,
interferon, ipilimumab, lapatinib, nivolumab, panitumumab, pembrolizumab,
pertuzumab, sorafenib, trastuzumab emtansin, temsorilimus, vemurafenib, ibandronik
asit, pamidronat, bexarotan, buserelin, siproteron, degareliks, folinik asit, fulvestrant,
lanreotid, lenalidomid, letrozole, leuprorelin, megestrol, mesna, talidomid°den olusan
bir grubun içerisinden veya bunlarin ikili veya üçlü kombinasyonlari içerisinden
seçilebilir.
Bulusun bir diger uygulamasinda en az bir diger etken madde bulusa uygun Formül I,
bilesikleriyle beraber veya ayri ayri formüle edilebilir ve söz konusu en az bir diger
etken madde Formül I, Formül II, Formül III, Formül IV, Formül V, Formül VI,
Formül VII, Formül VIII bilesikleriyle ayni veya farkli dozaj formunda olabilir.
Bulusa uygun Formül I, Formül II, Formül III, Formül IV, Formül V, Formül VI,
Formül VII, Formül VIII bilesikleriyle beraber yukarida sayilan en az bir diger etken
maddenin kullanilmasi durumunda söz konusu diger etken maddeler Formül I, Formül
maddelerle ayni zamanda, birbirini takip eder sekilde sirali olarak veya birbirinden
Bulusa uygun formülasyonlar Formül I, Formül II, Formül III, Formül IV, Formül V,
Formül Vl, Formül VII, Formül Vlll ile gösterilen etken maddelere ilaveten en az bir
yardimci madde içerebilir.
Bulusa uygun Formül 1, FOrinül ll, Formül [11, Formül lV, Formül V, Formül Vl,
Formül Vll, Formül VIII ile gösterilen etken maddelerin kullanilabilecegi doz araligi
hastanin ihtiyaçlari, hastaligin evresi ve kullanilacak etken maddeye göre belirlenir.
Belirli bir duruma uygun dozun belirlenmesi teknigin bilinen durumunda yetkili
kisilerce bilinmektedir.
Bu tarifname baglaminda içerir ifadesinin kapsar ifadesini belirtmesi amaçlanmistir.
Teknik açidan uygun olan yerlerde, bulusun uygulamalari birlestirilebilir.
Uygulamalar burada belirli özellikler/elemanlar içerecek sekilde açiklanmistir.
Tarifname ayrica esas olarak bahsi geçen özellikleri/elemanlari içeren ya da bunlardan
meydana gelen diger uygulamalari da kapsamaktadir.
Patentler ve basvurular benzeri teknik referanslar referans yolu ile bu dokümana dahil
edilmistir.
Burada spesifik olarak ve açikça anlatilan uygulamalar tek basina ya da bir veya
birkaç diger uygulama ile birlikte bir feragatnameye esas teskil edebilir.
Simdi bulus sadece örnek amaçli olan ve bu bulusun kapsamini herhangi bir sekilde
kisitlar olarak yorumlanmamasi gereken asagidaki örneklere atifta bulunularak
açiklanacaktir.
ÖRNEKLER:
Örnek 1: 2-(3-hidr0ksipr0pil)-lH-benzo[de]izokinolin-l,3(2H)-dion (Formül X)
sentez yöntemi
DMF içerisinde çözülen 4-amino-1,8-naftalik anhidrit (l mmol) çözeltisinin içerisine
3-Amino-1-propanol (1 mmol) ve DBU (1 mmol) ilave edilerek 4 saat boyunca 70°C
sicaklikta karismasi saglandi. Ardindan ortama buzlu su eklenerek olusan kati filtre
edildi ve ürün saf olarak elde edildi. Reaksiyonun ilerleyisi DCM/MeOH:40/ 1 çözücü
sistemi ile TLC çalismasi yapilarak kontrol edildi. (Verim: %98)
Analiz Verileri: LC-MS: m/z 256 [M+l]
Örnek 2: 3-(1,3-diokso-lH-benzo[de]isokinolin-2(3H)-il)propil metansulfonat
(Formül Y) sentez yöntemi
2-(3 -hidrokspropil)-1H-benzo[de]isokinolin-1,3(2H)-dion DCM”de çözüldü.
Ardindan ortaina TEA (1.2 mmol) eklendi ve 15 dakika boyunca OÜC de karismasi
saglandi. Sonra ortama para-metil sülfonil klorid (1.2 mmol) eklenerek 2 saat boyunca
reaksiyon karistirildi. Reaksiyonun ilerleyisi DCM/MeOH (10/1) çözücü sistemiyle
kontrol edildi. Reaksiyon buzlu suda çöktürme ve süzme ile sonlandirilarak ürün saf
olarak elde edildi. (Verim: %86)
Analiz Verileri: LC-MS: m/z 334 [MH]
Örnek 3: 2,2'-(((metilenbis(4,l-fenilen))bis(azandiil))bis-(pr0pan-3,l-diil))bis(ll-l-
ACN ortaminda 700C de 2 saat boyunca Formül Y°nin (l mmol) Nal (6 mmol) ile
karistirilmasi saglandi. Ayni zamanda baska bir reaksiyon balonunda
Diaminodifenilmetan (1 mmol) ve K2CO3 (6 mmol)` ün ACN ortaminda 70°C de 2
saat boyunca karismasi saglandi. Ardindan bu iki reaksiyon birbirine karistirilarak
reaksiyona devam edildi. TLC kontrolü yapilarak 12 saat sonunda reaksiyonun
çözücüsü vakumlu bir sistemde uzaklastirildi. Sonrasinda kloroforrn ve sulu NaCl
çözeltsi ile ektraksiyon yapilarak reaksiyon sonlandirildi. Organik faz kuru Na2804
içerisine konularak filtre edildi ve çözücüsü uzaklastirildi. Ürünün saIlastirilmasinda
DCM / MeOH (40: l) çözücü sistemi kullanilarak kolon kromatografîsi ile saflastirma
islemi gerçeklestirilmistir.
Analiz Verileri: LC-MS: m/z 436 [M+1].
2H, NHCHZ), , 6.52 - 6.48 (m,
4H, 4XArH), , 8.09
ACN ortaminda 700C de 2 saat boyunca Formül Y°nin (1 mmol) Nal (6 mmol) ile
karistirilmasi saglandi. Ayni zamanda baska bir reaksiyon balonunda Benzidin (l
mmol) ve K2C03 (6 mmol)” ün ACN ortaminda 70°C de 2 saat boyunca karismasi
saglandi. Ardindan bu iki reaksiyon birbirine karistirilarak reaksiyona devam edildi.
TLC kontrolü yapilarak 12 saat sonunda reaksiyonun çözücüsü vakumlu bir sistemde
uzaklastirildi. Sonrasinda kloroform ve sulu NaCl çözeltsi ile ektraksiyon yapilarak
reaksiyon sonlandirildi. Organik faz kuru NaZSO4 içerisine konularak filtre edildi ve
çözücüsü uzaklastirildi. Ürünün saflastirilmasinda DCM / MeOH (20: l) çözücü
sistemi kullanilarak kolon kromatografisi ile saflastirma islemi gerçeklestirilmistir.
Analiz Verileri: LC-MS: m/z 423 [M+1].
Örnek 5: 2-(3-((5-aminonaftalen-l -il)amino)propil)-l H-benzo[de]isokinolin-l ,3(2H)-
dion, (C25H21N302) (Formül 61) sentez yöntemi
ACN ortaminda 7OÜC de 2 saat boyunca Forinül Y”nin (1 mmol) NaI (6 mmol) ile
karistirilmasi saglandi. Ayni zamanda baska bir reaksiyon balonunda 1,5-
Diaminodifenilmetan (1 mmol) ve K2CO3 (6 mmol)* ün ACN ortaininda 700C de 2
saat boyunca karismasi saglandi. Ardindan bu iki reaksiyon birbirine karistirilarak
reaksiyona devam edildi. TLC kontrolü yapilarak 12 saat sonunda reaksiyonun
çözücüsü vakumlu bir sistemde uzaklastirildi. Sonrasinda kloroform ve sulu NaCl
çözeltsi ile ektraksiyon yapilarak reaksiyon sonlandirildi. Organik faz kuru Na2S04
içerisine konularak filtre edildi ve çözücüsü uzaklastirildi. Ürünün satlastirilmasinda
DCM / MeOH (25: 1) çözücü sistemi kullanilarak kolon kromatogratisi ile sat1astirma
islemi gerçeklestirilmistir.
Analiz Verileri: LC-MS: m/z 396 [M+1].
iH NMR (, 3.33 (t. J: 6.3 Hz,
2xArH) ppm.
Örnek 6: 2-(3-((8-amin0naftalen-1-il)amin0)propi1)-1H-benzo[de]isokinoline-
ACN ortaminda 7OÜC de 2 saat boyunca Formül Y”nin (1 ininol) Nal (6 mmol) ile
karistirilmasi saglandi. Ayni zamanda baska bir reaksiyon balonunda 1,8-
Diaminodifenilmetan (1 mmol) ve K2CO3 (6 mmol)` ün ACN ortaminda 700C de 2
saat boyunca karismasi saglandi. Ardindan bu iki reaksiyon birbirine karistirilarak
reaksiyona devam edildi. TLC kontrolü yapilarak 12 saat sonunda reaksiyonun
çözücüsü vakumlu bir sistemde uzaklastirildi. Sonrasinda kloroform ve sulu NaCl
çözeltsi ile ektraksiyon yapilarak reaksiyon sonlandirildi. Organik faz kuru Na2$O4
içerisine konularak filtre edildi ve çözücüsü uzaklastirildi. Ürünün saIlastirilmasinda
DCM / MeOH (100: l) çözücü sistemi kullanilarak kolon kromatografisi ile
saflastirma islemi gerçeklestirilmistir.
Analiz verileri: LC-MS: m/z 396 [M+l].
NHCHg), , 6.64 (d, J :
Hz, iH, A, 8.15 (dd, J
Örnek 7: Formül 9”un Leishmania Infantum Parazitlerine Karsi Biyolojik Aktivitesi
Metot ve Materyaller:
Parazit Kültürü: Leishmania infantum (MHOM/MA/67/lTMA-P263) promastigotlari
27°C5de RPMI mediumunda (isica inaktive ettirilmis %10 fetal bovin serum, 2 mM
L-glutamine, 20 mM HEPES, 100 U/ml penicillin, 100 ug/ml streptomisin esliginde)
inkübe edilir. Logaritmik faza ulasan parazitler(106/ml) enfektif hale getirilir.
Alamar Blue Hücre Canliligi Testi: Leishmania infantum (MHOM/MA/67/ITMA-
P263) promastigotlari 27°C”de RPMI mediumu içerisinde (isica inaktive ettirilmis
100 tig/ml streptomisin esliginde) 96 kuyucuklu kültür kaplarina (Coming Glasswork,
Coming, NY) 82:106 parazit/kuyucuk olacak sekilde ekildikten sonra 3. gün
parazitlerin canlilik düzeyleri Ölçülmüstür. Alamar Blue testi (Sigma-Aldrich,
Almanya) uygulanarak parazitlerin canliligi tespit edilir. lOOul büyüme besiyeri
içerisinde olan hücrelerin üzerine 10111 Alamar Blue solüsyonu eklenir ve bir gün
karanlikta inkübe edilir. Inkübasyon süresinden sonra 530/590 nm dalga boyunda
ELISA plaka okuyucu (Biotek, Winooski, VT) cihazi ile abzorbans ölçümü yapilarak
canlilik analizi gözlemlenir.
Bulus kapsaminda tanimlanan moleküllerden Formül 9,1117 Leishmania infantum
parazitleri üzerine olan etkisi gösterilmistir. Formül 9 bilesigi, parazitler üzerine
verilip 3 gün boyunca parazit canliligina bakildiginda, yaklasik % 45'e varan ölüm
orani gözlenmistir (Sekil 1). Yapilan deneyler isiginda, gelistirilen inolekülün
Leishmania infantum parazitleri üzerinde etkili olduguna ulasilmistir.
Claims (3)
- ISTEMLER l. Bisnaftalimidopropil (BNIP) türevi moleküller olup söz konusu moleküller; a) Formül 1; 5 b) Formül II; e) Formül V; R31 R32 I) Formül VI; g) Formül VII; R48R49 5 h) Formül VIII; -n 0 ile 12 arasinda bir dogal sayidirj birbirinden bagimsiz olarak; C1, F, Br, 1, -OH, -NO, -NOg, -COOH, -ORX, -SOZRX, -SOzNHRx, -SOzNRxRy, -CN, 15 NHCORX, -NHCONHRX, -NHSOzRX”den olusan bir grubun içerisinden; -H, -Cla -Fa -Br, -I, RX, -NHZ, -NHRX, -NRXRy, -OH, -NO, -NOZ, -COOH, -ORX, - COORx, -CN içerisinden; -H, -Cl, -F, -Br, -l, RX, -NHZ, -NHRX, -NRxRy, -OH, -COOH, -ORX, -COORX, -CN, - SO3H, -803_Na+, , , -NO içerisinden; NH2 NH2 NH2 H 7 H 3 H 7 NH2 NH2 S 9 H 7 O 5 H ”den olusan bir grubun içerisinden; -H, -Cl, -F, -Br, -i, RX, -NHZ, -NHRX, -NRxRy, -OH, -NO, -COOH, -ORX, -COORX, -CN”den olusan bir grubun içerisinden; RX, Ry ve R1 ise birbirinden bagimsiz olarak; ikameli veya ikamesiz Cl-C12 alkan, ikameli veya ikamesiz Cl-C12 alken, ikameli veya ikamesiz Cl-C12 alkin, ikameli veya ikamesiz Cl-C12 primer amin, ikameli veya ikamesiz C1-C12 sekonder amin, ikameli veya ikamesiz alkol, ikameli veya ikamesiz alkil siyanid, ikameli veya ikamesiz sülfonamid, ikameli veya ikamesiz Cl-Cl2 alkyl sülfonil, ikameli veya ikamesiz C3-C8 sikloalkil, ikameli veya ikamesiz aril, ikameli veya ikamesiz heteroaril, istege bagli olarak birbirinden bagimsiz olarak 0, S ve N içerisinden seçilen bir veya daha fazla heteroatom içeren ikameli veya ikamesiz heterosiklik veya heteroatomatik halkalardan olusan grubun içerisinden seçilir.
- 2. Istem lie göre bisnaftalimidopropil (BNIP) türevi moleküller olup; Formül 1 ile gösterilen moleküllerde veya 12 degerini alir; sozcnzcnzcm, -SOZCHZCH2CH2CH3, -SOZCHZCHZCHZCHQCHg, cocnzcnzcnzcm, -COCHZCHZCHZCHZCHg, -COCHzCHzCHzCHgCHQCHg, NHCOCH(CHZSH)(NH2), -Nncocmcnzcnzsmmng, - NHSOZCHZCHZN(CH, - NHCHgCHgSOgNHCHg., -NHCHZCHZSOZN(CH3)2”den olusan bir grubun içerisinden seçilir.
- 3. Istem 1 ve 2°ye göre bisnaftalimidopropil (BNIP) türevi moleküller olup Formül Pde n:0 oldugunda R4 ve R5 hostur. Istem l"e göre bisnaftalimidopropil (BNIP) türevi moleküller olup, formül H ile bagimsiz olarak; -H, -Cl, -F, -Br, -I, -NHz` -CH3, C(CH3)2'den olusan bir grubun içerisinden seçilir. Istem l”e göre bisnaftalimidopropil (BNIP) türevi moleküller olup formül V ile olarak -H, -NHZ, -OCH3, -NO, -Cl, F, I, Br,dan olusan bir grubun içerisinden seçilir. Istem 1°e göre bisnaftalimidopropil (BNIP) türevi moleküller olup formül VI ile bagimsiz olarak; -H, -NH2, -CH3, -CH2CH3, -CHzCHzCH3, -C(CH3)3, Cl, F, Br, I, COOCH3, -COONHZ, -COONHCHg, -COON(CH3)2°den olusan bir grubun içerisinden seçilir. Istem l”e göre bisnaftalimidopropil (BNIP) türevi moleküller olup formül VII ile bagimsiz olarak; -H, -NH2, -CH3, -CH2CH3, -CHzCHzCH3, -C(CH3)3, Cl, F, Br, I, COOCH3, -COONHg, -COONHCHg, -COON(CH3)2°den olusan bir grubun içerisinden seçilir. Istem l”e göre bisnaftalimidopropil (BNIP) türevi moleküller olup formül VIII ile bagimsiz olarak; -H, -NHz, -CH3, -CHgCH3, -CHgCHgCHg, -C(CH3)3, Cl, F, Br, 1, COOCH3, -COONHz, -COONHCHg, -COON(CH3)2°den olusan bir grubun içerisinden seçilir. Istem türevi moleküller olup Formül Vl, VII ve VIII ile gösterilen moleküllerde R1 -H`dir. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 1 ile gösterilen yapiya sahiptir. ll. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 2 ile gösterilen yapiya sahiptir. 12. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 3 ile gösterilen yapiya sahiptir 13. Istem lie göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 4 ile gösterilen yapiya sahiptir 14. Istem 1”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 5 ile gösterilen yapiya sahiptir 15. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 6 ile gösterilen yapiya sahiptir 16. Istem 1”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül 5 formül 7 ile gösterilen yapiya sahiptir 17. Istem lie göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 8 ile gösterilen yapiya sahiptir türevi molekül formül 9 ile gösterilen yapiya sahiptir 19. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 10 ile gösterilen yapiya sahiptir 20. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül l 1 ile gösterilen yapiya sahiptir 21. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 12 ile gösterilen yapiya sahiptir 22. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 13 ile gösterilen yapiya sahiptir 23. Istem l”e göre formül 1 ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 14 ile gösterilen yapiya sahiptirO 24. Istem 1”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 15 ile gösterilen yapiya sahiptir 25. Istem 1 e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 16 ile gösterilen yapiya sahiptir 26. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 17 ile gösterilen yapiya sahiptir 27. Istem 1”e göre formül 1 ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 18 ile gösterilen yapiya sahiptir 28. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 19 ile gösterilen yapiya sahiptir 29 Istem l e göre formül 1 ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 20 ile gösterilen yapiya sahiptir 30. Istem 1”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 21 ile gösterilen yapiya sahiptir 31. lstem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 22 ile gösterilen yapiya sahiptir 32. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 23 ile gösterilen yapiya sahiptir 33. Istem lie göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 24 ile gösterilen yapiya sahiptir 34. Istem 1”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 25 ile gösterilen yapiya sahiptir 35. Istem 1”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 26 ile gösterilen yapiya sahiptir 36. Istem lie göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 27 ile gösterilen yapiya sahiptir türevi molekül formül 28 ile gösterilen yapiya sahiptir 38. Istem 1”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 29 ile gösterilen yapiya sahiptir 39. Istem 1”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 30 ile gösterilen yapiya sahiptir 40. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 31 ile gösterilen yapiya sahiptir türevi molekül formül 32 ile gösterilen yapiya sahiptir 42. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 33 ile gösterilen yapiya sahiptir 43. Istem 1”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 34 ile gösterilen yapiya sahiptir 44. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 35 ile gösterilen yapiya sahiptir türevi molekül formül 36 ile gösterilen yapiya sahiptir 46. Istem l”e göre formül 1 ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 37 ile gösterilen yapiya sahiptir 47. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 38 ile gösterilen yapiya sahiptir 48. Istem 1”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül 5 formül 39 ile gösterilen yapiya sahiptir 49. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 40 ile gösterilen yapiya sahiptir türevi molekül formül 41 ile gösterilen yapiya sahiptir 51. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 42 ile gösterilen yapiya sahiptir 52. Istem l”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 43 ile gösterilen yapiya sahiptir türevi molekül formül 44 ile gösterilen yapiya sahiptir 54. Istem 1”e göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 45 ile gösterilen yapiya sahiptir 55. Istem lie göre formül I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 46 ile gösterilen yapiya sahiptir türevi molekül formül 47 ile gösterilen yapiya sahiptir 57. Istem 1”e göre formül H ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 48 ile gösterilen yapiya sahiptir 58. Istem Pe göre formül H ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 49 ile gösterilen yapiya sahiptir 59. Istem 1”e göre formül H ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 50 ile gösterilen yapiya sahiptir 60. Istem 1 e göre formül II ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 51 ile gösterilen yapiya sahiptir 61. Istem 1,e göre formül II ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 52 ile gösterilen yapiya sahiptir 62. Istem l°e göre formül [I ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 53 ile gösterilen yapiya sahiptir 63. Istem 1”e göre formül H ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 54 ile gösterilen yapiya sahiptir 64. Istem 1 e göre formül III ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 55 ile gösterilen yapiya sahiptir 65.Istem l°e göre formül türevi molekül formül 56 ile gösterilen yapiya sahiptir 66. Istem l”e göre formül türevi molekül formül 57 ile gösterilen yapiya sahiptir 67.Istem l'e göre formül türevi molekül formül 58 ile gösterilen yapiya sahiptir 68.Istem l'e göre formül türevi 5 molekül formül 59 ile gösterilen yapiya sahiptir 69. Istem lje göre formül III ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 60 ile gösterilen yapiya sahiptir türevi molekül formül 61 ile gösterilen yapiya sahiptir 7l.lstem l”e göre formül türevi molekül formül 62 ile gösterilen yapiya sahiptir 72.Istem 1”e göre formül IV ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 63 ile gösterilen yapiya sahiptir türevi molekül formül 64 ile gösterilen yapiya sahiptir 74.lstem l”e göre formül IV ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 65 ile gösterilen yapiya sahiptir 75.Istem l°e göre formül IV ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 66 ile gösterilen yapiya sahiptir 76. Istem 1”e göre formül IV ile gösterilen bisnaftalimidoprOpil (BNIP) türevi molekül formül 67 ile gösterilen yapiya sahiptir türevi molekül formül 68 ile gösterilen yapiya sahiptir 78. Istem 1°e göre formül [V ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 69 ile gösterilen yapiya sahiptir 79. Istem türevi molekül formül 70 ile gösterilen yapiya sahiptir 80. Istem l°e göre formül IV ile gösterilen bisriaftalimidopropil (BNIP) türevi molekül formül 71 ile gösterilen yapiya sahiptir türevi molekül formül 72 ile gösterilen yapiya sahiptir 82. Istem l”e göre formül IV ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 73 ile gösterilen yapiya sahiptir 83.Istem l°e göre formül IV ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 74 ile gösterilen yapiya sahiptir 84.Istem l°e göre formül IV ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 75 ile gösterilen yapiya sahiptir türevi molekül formül 76 ile gösterilen yapiya sahiptir 86. Istem 1”e göre formül [V ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 77 ile gösterilen yapiya sahiptir 87.Istem 17e göre formül IV ile gösterilen bisnaftalimidopropi] (BNIP) türevi molekül formül 78 ile gösterilen yapiya sahiptir 88.Istem 1”e göre formül IV ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 79 ile gösterilen yapiya sahiptir türevi molekül formül 80 ile gösterilen yapiya sahiptir 90. Istem l”e göre formül IV ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 81 ile gösterilen yapiya sahiptir 91.Istem 1”e göre formül [V ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 82 ile gösterilen yapiya sahiptir 92.lstem 1”e göre formül IV ile gösterilen bisnaftalimidoprOpil (BNIP) türevi molekül formül 83 ile gösterilen yapiya sahiptir türevi molekül formül 84 ile gösterilen yapiya sahiptir 94. Istem l°e göre formül IV ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 85 ile gösterilen yapiya sahiptir 95.Istem 17e göre formül IV ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 86 ile gösterilen yapiya sahiptir 96. Istem l'e göre formül V ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 87 ile gösterilen yapiya sahiptir 0 H2N:. 97. Istem 1”e göre formül V ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül 5 formül 88 ile gösterilen yapiya sahiptir 98. Istem lie göre formül V ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül formül 89 ile gösterilen yapiya sahiptir türevi molekül formül 90 ile gösterilen yapiya sahiptir türevi molekül formül 91 ile gösterilen yapiya sahiptir türevi molekül formül 92 ile gösterilen yapiya sahiptir türevi molekül formül 93 ile gösterilen yapiya sahiptir türevi molekül formül 94 ile gösterilen yapiya sahiptir türevi molekül formül 95 ile gösterilen yapiya sahiptir türevi molekül formül 96 ile gösterilen yapiya sahiptir Istem l e göre formül VIII ile gösterilen bisnaftalimidopropil (BNIP) türevi molekül Iormül 97 ile gösterilen yapiya sahiptir türevi molekül formül 98 ile gösterilen yapiya sahiptir türevi molekül formül 99 ile gösterilen yapiya sahiptir türevi moleküllerin hazirlanmasinda kullanilacak bir metot olup; a) Formül X ile gösterilen maddenin çözücü varliginda para-metil sülfoiiil klorid ile reaksiyona sokulmasi, Formül X b) Olusan ara ürünün (Formül Y) Çözücü varliginda Nal ile karistirilmasi ve bu karisima çözücü, tercihen asetonitril içerisinde, diamino bilesigi ile K2C03 5 çözeltisi ilave edilmesi 0) Son ürünün reaksiyon karisimindan izole edilmesi adimlarini içerir. 110. Istem 109”a göre bir metot olup, a) ve b) adiminda kullanilacak çözücü asetik 10 asit, aseton, asetonitril, benzen, l-butanol, 2-butanol, 2-butanon, t-butil alkol, karbon tetraklorür, klorobenzen, kloroform, siklohekzan, 1,2-dikloroetan, dietilen glikol, dietileter, dietilen glikol dimetil eter, , dimetilformamid (DMF), dimetilsülfoksit (DMSO), 1,4-dioksan, etanol, etil asetat, etilen glikol, gliserin, heptan, hekzametilfosforamid (HMPA), 15 hekzametilfosforus triamid (HMPT), hekzan, metanol, metilt-bütil eter (MTBE), metilen klorür (DCM), N-metil-Z-pirolidon (NMP), nitrometan, pentan, petrol eteri, l-propanol, 2-propanol, piridin, tetrahidrofuran (THF), tolüen, trietil amin, su, o-ksilen, m-ksilen, p-ksilen'den olusan bir grubun içerisinden seçilir. 20 diklorometan ve b) adiminda çözücü olarak asetonitril kullanilir. veya 25-80 0C araliginda bir sicaklikta gerçeklestirilir. 113. Istem 1-108”e göre Formül I, Formül II, Formül III, Formül IV, Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen bisnaftalirnidopropil (BNIP) türevi moleküllerin bakteriyel, viral, parazitik ve neoplastik hastaliklarin tedavisinde ilaç olarak kullanimi. 114. Istem 113°e göre bir kullanim olup parazitik hastalik sistozomiyaz, opistorsiyaz. klonorkiyaz, dikrosölyoz, fasioliyazis, paragonimiyaz, fasiolopsiyaz, ekinokokiyaz, tenyazis, sistiserkoz, difilobotrtyaz, sparganoz, himenolepiyaz, drakunkuliyaz, onkoserkiyazis, filaryaz, elefantiyazis, mansonelloz, trisinelozis, ankilostomiyaz, nekatoryaz, ankilostomyazis, askardiyoz, strongiloidiyaz, trisüriyaz, enterobiyazis, anisakiyaz, helniintiyazis, trikostronjiloz, anjiyostrongiloz, gnatostomiyaz, anjiyostrongiloz, singamiyaz, hirudiniyaz, akantosefallyaz, gongilonemiyaz, metastrongilyaz, telaziyaz, pediküloz, pithiriyaz, skabiyez, miyaz, tungiyaz, trombikuloz, skarabiazis, hirudiniyaz, linguatuloz, porosefaliyaz, leishmania, trypanosomiasis, plazmodyum falsiparum”un neden Oldugu malarya, plazmodyum vivaxîn neden oldugu malarya, plazmodyum malariae”nin neden oldugu malarya, Chagas hastaligi, toksoplazma, pnömosistoz, babeziyoz, piroplazmoz, akantamebiyaz, naegleriyaz ve/veya mikrosporidioz olabilir. Istem 114,e göre bir kullanim olup parazitik hastalik leishmaniasis`tir. 116. Istem 113le göre bir kullanim olup parazitik hastalik L. Arabica, L. archibaldi', L. aristedesi, L. braziliensis, L. chagasi, L. colombiensis,L. Deanei, L. donovani, L. enrietii, L. equaforensis, L. forattinii, L. gamhami, L. gerbil, Lguyanensis, L. herreri. L. hertigi, L. Infantum, L. killz'ckz', L. lainsoni', L. major, L. Mexicana, L. nagjî, L. panamensis, L. pemviana, L. pifanoi, L. Shawi, L. tarenrolae, L. tropi'ca, L. turam'ca, L. venezuelensi's türü parazitlerin neden oldugu bir hastaliktir. 117. Istem 113,6 göre bir kullanim olup bakteriyel hastalik basili, bartnnella, bordetella, borrelia, brusella, kampilobakter, kalamidya, kalamidofila, klostridyum, korinebakteryum, enterokokkus, eserya, fransiyella, hemofilus, helikobakter, lejyonella, leptospira, listeria, mikobakteryum, mikoplazma, nisserya, psödomonas, riketsiya, salmonella, sigella, statilokokkus, streptokokkus, treponema, üreplazma, vibrio, yersinia, ana gruplarina mensup bakteriler nedeniyle olusan herhangi bir bakteriyel hastaliktir. Istem ll7”ye göre bir kullanim olup bakteriyel hastalik bubonic veba, pnömonik veba, kolera, sifilis, konjenital sifilis, post streptokoksik glomerulonefrit, lohusa hummasi, impetigo, yilancik, atesli romatizma, kizil, streptokokkal faranjit, sepsis, akut bakteriyel pnömoni, menenjit, orta kulak iltihabi, endometrit, neonatal sepsis, neonatal menenjit, neonatal pnömoni, sistit, osteomiyelit, toksik sok sendromu, stafilokokkal gida zehirlenmesi, sigelloz, salmonella, paratifo, tifo, kayalik daglar lekeli hummasi, idrar yolu enfeksiyonlari, kornea enfeksiyonlari, pnömoni, endokardit, menenjit, gnore, pelvik enflamatuar hastaligi, tüberküloz, cüzzam, listeriyoz, leptospiroz, lejyoner hastaligi, peptik ülser, üst solunum yolu enfeksiyonlari, kronik gastrit, bronsit, septik artrit, tularemia, kanli diyare, idrar yolu enfeksiyonlari, endokardit, safra yolu enfeksiyonlari, difteri, tetanoz, papagan hummasi, trachoma, neonatal konjuktivit, üretrit, epididimit, prostatit, lenfogranülomatoz, atipik pnömoni, Guillain-Barre Sendromu, broselloz, malta hummasi, lyme hastaligi olabilir. 119. Istem 113”e göre bir kullanim olup viral hastalik adenoviridae, herpesviridae, papillomaviridae, polyomaviridae, poxviridae, heradnaviridae, parvoviridae, astroviridae, caliciviridae, picornaviridae, coronaviridae, flaviviridae, togaviridae, hepeviridae, retroviridae, ortomiksoviridae, arenaviridae, bunyaviridae, filoviridae, paramiksoviridae, rabdoviridae, reoviridae ana ailelerine mensup olan herhangi bir virüsün neden oldugu bir hastalik olabilir. Istem ll9`a göre bir kullaniin olup Viral hastalik gasteroentirit, keratokonjuktivit, farenjit, krup, pnömoni, sistit, el-ayak-agiz hastaligi, pleurodnia, septik menenjit, perikadit, miyokardit, Burkitt”e Lenfoma, Hodgin”s lenfoma, nasafaranjiyel karsinom, akut hepatit, kronik hepatit, hepatic siroz, hepatoselüler karsinom, tonsilit, sitomegalik inklüzyon hastaligi, Kaposi sarkomu, castleman hastaligi, influenza, kizamik, reye sendromu, kabakulak, anogenital sigil, poliomiyellit, kuduz, konjenital rubella, kizamikçik, çiçek hastaligi, zona, konjenital su çiçegi sendromu olabilir. Istem 113,e göre bir kullanim olup neoplastik hastalik kanser hastaligi örnegin; karsinoma, lenfoma, blastoma sarkoma veya lösemi olabilir. Istem 121°e göre bir kullanim olup kanser hastaligi; meme kanseri, prostat kanseri, kolorektal kanser, deri kanseri, küçük hücreli akciger kanseri, küçük hücreli olmayan akciger kanseri, mezotelyom, gastrointestinal kanser, pankreas kanseri, gliyoblastom, vulva kanseri, rahim agzi kanseri, endometriyal karsinom, yumurtalik kanseri, karaciger kanseri, hepatom, mesane kanseri, böbrek kanseri, tükürük bezi karsinomu, tiroid kanseri ve çesitli bas ve boyun kanserleri olabilir. 123. Istem 1-108”e göre Formül 1, Formül II, Formül III, Formül IV, Formül V, Formül VI, Forinül Vll, Formül VIII ile gösterilen bilesikleri içeren farmasötik bilesimler. Formül IV, Formül V, Formül VI, Formül VII, Formül VIII ile gösterilen bilesiklere ilaveten en az bir diger etken madde içerir. 125. Istem 124°e göre farmasötik bilesim olup diger etken madde antiparazitik, antibakteriyel, antiviral, antineoplastik ve/veya sitotoksik ve/veya antimetastatik etki gösteren bilinen aktif bilesiklerle veya bunlarin ikili, üçlü kombinasyonlari içerisinden seçilir. 126. Istem 125°e göre farmasötik bilesim olup antibakteriyel etki gösteren aktif bilesik amikasin, gentamisin, kanamisin, neomisin, netilmisin, tobramisin, paromisin, streptomisin, Spektinomisin, geldanamisin, herbimisin, rifaksimin, lorakarbef, ertapenem, doripenem, imipenem, meropenem, sefadroksil, sefazolin, sefalotin, sefaleksin, sefaklor, sefamandol, sefoksitin, sefprozil, sefuroksim, sefiksim, sefdinir, sefditoren, sefoperazon, sefotaksim, sefpodoksim, seftazidim, seftibüten, seftizoksim, sefepim, seftarolin fosamil, seftobiprol, teikoplanin, vankomisin, televansin, dalbavansin, oritavansin, clindamisin, linkomisin, daptomisin, azitromisin, klaritromisin, diritromisin, eritromisin, roksitromisin, troleandomisin, telitromisin, spiramisin, aztreonam, furazolidon, nitrofurantoin, linezolid, posizolid, radezolid, torezolid, amoksisilin, ampisilin, azlosilin, karbenisilin, kloksasilin, dikloksasilin, flukloksasilin, mezlosilin, metisilin, nafsilin, okzasilin, penisilin G, penisilin V, piperasilin, temosilin, tikarsilin, klavulanat, sulbaktam, tazobaktam, basitrasin, kolistin, polimiksin B, siprofloksasin, enoksasin, gatifloksasin, geinifloksasin, levofloksasin, lometloksasin, moksitloksasin, nalidinik asit, nortloksasin, oIloksasin, trovaIloksasin, grepafloksasin, sparfloksasin, temafloksasin, mafenid, sulfasetamid, sulfadiazin, sülfadimetoksin, sülfametizol, sülfametoksazol, sulfanilimid, sülfasalazin, sülfisoksazol, trometoprim, demeklosiklin, doksisiklin, minosiklin, oksitetrasiklin, tetrasiklin, klofazimin, dapson, kapreomisin, sikloserin, etambutol, isoniyazid, pyrazinamid, rifampisin, rifabutin, rifapentin, streptomisinj arsfenaminj kloramfenikol, fosfomisin, fusidik asit, metronidazol, mupirosin, platensimisin, kinupristin, dalfopristin, tiamfenikol, tigesiklin, tinidazol, trimetoprim”i içeren grubun içerisinden veya burada sayilan ajanlarin ikili veya üçlü kombinasyonlari içerisinden seçilir. lstem 125,e göre bir farmasötik bilesim olup antiviral etki gösteren aktif bilesikler abakavir, asiklovir, adefovir, amantadin, amprenavir, ampligen, arbidol, atazanavirj atripla, balavir, sidofovir, kombivir, dolutegravir, darunavir, delavirdin, didanosin, dokosanol, eduksudin, efavirenz, emtrisitabin, enfuvirtid, entekavir, ekoliver, famsiklovir, fomivirsen, fosamprenavir, foskamet, fosfonet, gansiklovir, ibasitabin, imunovir, idoksuridin, imikuimod, indinavir, inosin, interferon tip I, interferon tip II, interferon tip [II, interferon, lamivudin, lopinavir, lovirid, maravirok, moroksidin, metisazon, nelfinavir, nevirapin, neksavir, nitazoksanid, novir, oseltamivir, peginterferon alfa-Za, pensiklovir, peramivir, plekonaril, podofilotoksin, proteaz inhibitörû, nükleosit analoglari, ralgetavir, ribavirin, rimantadin, ritonavir, piramidin, saquinavir, sofosbuvir, stavudin, telaprevir, tenofovir, tipranavir, trifliridine, trizivir, tromantadin, trovada, valasiklovir, valgansiklovir, Vidarabin, Viramidin, zalsitabin, zanamivir, zidovudin°i içeren grubun içerisinden veya burada sayilan ajanlarin ikili veya üçlü kombinasyonlari içerisinden seçilir. Istem 12576: göre bir farmasötik bilesim olup antiparazitik etki gösteren aktif bilesikler nitazoksanit, melarsoprol, eIlornitin, metronidazol, tinidazol, miltefosin, mebendazol, pirantel pamoat, tiyabendazol, dietilkarbamazinj ivermektin, niklosamid, prazikuantel, albendazol, rifampin, amfoterisin B, fumagillin, furazolidon, nifursemizon, nitaksozanid, ornidazol, paramomisin sülfat, pentamidin, pirimetamine, tinidazol, albendazol, mebendazol, tiyabendazol, fenbendazol, triklabendazol, flubendazol, abamektin, dietilkarbamazin, ivermektin, suramin, pirantel pamoatn levamisol, niklosamid, nitasokzanid, oksiklonazd, monepantelj derquantel, amfoterisin B, üre stibamin, sodyum stiboglukonat, meglumin antimoniat, paromomisin, miltefosin, Ilukonazol, pentamidin,den olusan bir grubun içerisinden veya bunlarin ikili, üçlü kombinasyonlari içerisinden seçilir. Istem 125,e göre bir fannasötik bilesim olup antineoplastik etki gösteren aktif bilesikler siklofosfamid, ifosfamid, temozolomid, kapesitabin, 5-Ilor0 urasil, metotreksat, gemsitabin, pemetrekset, mitomisin, bleomisin, epirubisin, doksorubisin, etoposit, paklitaksel, irinotekan, dosetaksel, Vinkristin, karboplatin, cisplatin, okzaliplatin, bevacizumab, setuksimab, gefîtinib, imatinib, trastuzumab, denosumab, rituksimab, sunitinib, zoledronat, abirateron, anastrozol, bikalutamid, eksemestan, goserelin, medroksiprogesteron, oktreotid, tamoksifen, bendamustin, karmustin, klorambusil, lomustin, melfalan, prokarbazina streptozosinj Iludarabin, raltitrexed, aktinomisin D, daktinomisin, doksorubisin, mitoksantron, eribulin, topotekan, vinblastin, vinorelbin, afatinib, ailibersept, krizotinib, dabrafenib, interferon, ipilimumab, lapatinib, nivolumab, panitumumab, pembrolizumab, pertuzumab, sorafenib, trastuzumab emtansin, temsorilimus, vemurafenib, ibandronik asit, pamidronat, bexarotan, buserelin, siproteron, degareliks, folinik asit, fulvestrant, lanreotid, lenalidomid, letrozole, leuprorelin, megestrol, mesna, talidomid`den olusan bir grubun içerisinden veya bunlarin ikili veya üçlü kombinasyonlari içerisinden seçilir. Istem 123-129°dan herhangi birine göre bir farrnasötik bilesim olup en az bir yardimci madde içerir.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2018/20740A TR201820740A2 (tr) | 2018-12-27 | 2018-12-27 | Özgün bi̇snaftali̇mi̇dopropi̇l (bnip) türevi̇ akti̇f i̇laç etken maddeleri̇ |
PCT/TR2019/051195 WO2020139291A1 (en) | 2018-12-27 | 2019-12-24 | Naphthalimide derivatives as anti-parasitic agents for the treatment of leishmaniasis as well as viral, bacterial and neoplastic diseases |
US17/417,143 US20220143005A1 (en) | 2018-12-27 | 2019-12-24 | Naphthalimide derivatives as anti-parasitic agents for the treatment of leishmaniasis as well as viral, bacterial and neoplastic diseases |
EP19845839.0A EP3902788B1 (en) | 2018-12-27 | 2019-12-24 | Naphthalimide derivatives as anti-parasitic agents for the treatment of leishmaniasis as well as viral, bacterial and neoplastic diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2018/20740A TR201820740A2 (tr) | 2018-12-27 | 2018-12-27 | Özgün bi̇snaftali̇mi̇dopropi̇l (bnip) türevi̇ akti̇f i̇laç etken maddeleri̇ |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201820740A2 true TR201820740A2 (tr) | 2020-07-21 |
Family
ID=69411493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2018/20740A TR201820740A2 (tr) | 2018-12-27 | 2018-12-27 | Özgün bi̇snaftali̇mi̇dopropi̇l (bnip) türevi̇ akti̇f i̇laç etken maddeleri̇ |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220143005A1 (tr) |
EP (1) | EP3902788B1 (tr) |
TR (1) | TR201820740A2 (tr) |
WO (1) | WO2020139291A1 (tr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112379029B (zh) * | 2020-11-10 | 2022-03-08 | 苏州艾迪迈医疗科技有限公司 | 一种检测血液中抗新型冠状病毒药物浓度的方法 |
CN117105810B (zh) * | 2023-10-23 | 2024-02-09 | 中国农业大学 | 一种具有广谱抗菌活性的化合物及其抗菌组合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201618160A2 (tr) * | 2016-12-09 | 2018-06-21 | T C Istanbul Medipol Ueniversitesi | Parazi̇ti̇k ve neoplasti̇k hastaliklarin tedavi̇si̇nde kullanima uygun özgün i̇laç molekülleri̇ ve bunlarin hazirlanmasinda kullanilacak usuller |
-
2018
- 2018-12-27 TR TR2018/20740A patent/TR201820740A2/tr unknown
-
2019
- 2019-12-24 EP EP19845839.0A patent/EP3902788B1/en active Active
- 2019-12-24 US US17/417,143 patent/US20220143005A1/en active Pending
- 2019-12-24 WO PCT/TR2019/051195 patent/WO2020139291A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020139291A1 (en) | 2020-07-02 |
EP3902788B1 (en) | 2024-02-21 |
EP3902788A1 (en) | 2021-11-03 |
US20220143005A1 (en) | 2022-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2855050T3 (es) | Derivado de piridinamidopirimidina, método de preparación y utilización del mismo | |
KR102405452B1 (ko) | 섬유아세포 성장 인자 수용체의 억제 | |
TW201910314A (zh) | 新穎化合物 | |
JP2020508302A (ja) | Nlrp3修飾因子としての置換されたイミダゾキノリン類 | |
KR20200028966A (ko) | Efgr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제 | |
JP5689069B2 (ja) | ピラゾロピリジンpi3k阻害剤化合物及び使用方法 | |
AU2020253633A1 (en) | STAT degraders and uses thereof | |
JP2010502650A (ja) | Raf阻害化合物およびその使用法 | |
CA2955082A1 (en) | Uses of salt-inducible kinase (sik) inhibitors | |
JP7159282B2 (ja) | Nlrp3モジュレーター | |
JP2022523201A (ja) | Ras阻害剤としての新規イソインドリノン置換インドールおよび誘導体 | |
JP2013503194A (ja) | Rafキナーゼを阻害するための1H−ピラゾロ[3,4−B]ピリジン化合物 | |
JP2022551422A (ja) | ピリドン化合物およびタンパク質キナーゼの調節における使用の方法 | |
TW202019426A (zh) | 以喹唑啉化合物作為有效成分之醫藥組成物 | |
TR201618160A2 (tr) | Parazi̇ti̇k ve neoplasti̇k hastaliklarin tedavi̇si̇nde kullanima uygun özgün i̇laç molekülleri̇ ve bunlarin hazirlanmasinda kullanilacak usuller | |
TR201820740A2 (tr) | Özgün bi̇snaftali̇mi̇dopropi̇l (bnip) türevi̇ akti̇f i̇laç etken maddeleri̇ | |
JP2024509192A (ja) | Hpk1アンタゴニスト及びその使用 | |
WO2015021894A1 (zh) | 新型羟肟酸衍生物及其医疗应用 | |
CN113366008B (zh) | 一种cd73抑制剂,其制备方法和应用 | |
JP7335341B2 (ja) | Nlrp3モジュレーター | |
EP4121055A1 (en) | Stat degraders and uses thereof | |
US11827597B2 (en) | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | |
WO2020082817A1 (zh) | 肟基萘醌类化合物及其制备方法和用途 | |
WO2023030335A1 (zh) | 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法 | |
CA3215081A1 (en) | Mek inhibitors and uses thereof |